Updated on 2024/12/03

Information

 

写真a

 
HIRAKAWA MASAKAZU
 
Organization
Beppu Hospital Department of Radiology Professor
Title
Professor
Contact information
メールアドレス
Tel
0977211609
Profile
Research and Education IVR Abdominal imaging
External link

Degree

  • DOCTOR OF PHILOSOPHY (Medical Science)

Research Interests・Research Keywords

  • Research theme： Development of Radiation protective device during Interventional radiology

    Keyword： Radiation protective device ,Interventional radiology

    Research period： 2023.4 - 2027.3

  • Research theme： Radiation protection during Interventional radiology

    Keyword： Radiation protection Interventional radiology

    Research period： 2021.4 - 2023.3

  • Research theme： Radiation protection during Interventional radiology

    Keyword： Radiation protection Interventional radiology

    Research period： 2020.4 - 2021.3

  • Research theme： Assessment of improvement of efficacy transarterial chemoembolization for hepatocellular carcinoma Assessment of the radiation dose reduction of patients and physicians during Interventional radiological procedure

    Keyword： HCC,TACE,Radiation dose,IVR

    Research period： 2015.4 - 2020.3

  • Research theme： Analysis of radiosentization controlling microRNA for esophageal carcinoma

    Keyword： esophageal carcinoma radiosentization microRNA

    Research period： 2011.4 - 2013.5

  • Research theme： Research of radiation sensitizer to malignant tumor

    Keyword： radiation sensitizer malignant tumor

    Research period： 2009.4 - 2011.3

  • Research theme： Research of radiation sensitizer to malignant tumor

    Keyword： radiation sensitizer to malignant tumor

    Research period： 2005.4 - 2009.3

Awards

  • 第3回Interventional Radiology優秀論文賞

    2019.5   日本IVR学会   Interventional Radiology 2018 Best Paper Award Midterm Outcomes and Prognostic Factors of Patients Treated Using Microballoon-Occluded Transarterial Chemoembolization with Miriplatin: A Retrospective Study of 37 Cases

    　More details

    Purpose: This study aimed to retrospectively evaluate the overall survival and prognostic factors of patients
    treated using microballoon-occluded transarterial chemoembolization (B-TACE) with miriplatin for hepatocellular
    carcinoma (HCC).
    Materials and Methods: Thirty-seven patients (23 men and 14 women; mean age, 74.1 years; Barcelona
    Clinic Liver Cancer stage A:21, B:10, C:6; first TACE, 17) treated using B-TACE with miriplatin were retrospectively
    analyzed. Overall survival and progression-free survival were analyzed using Kaplan-Meier methods,
    and a multivariate analysis was performed to identify prognostic factors. Side effects were analyzed on
    the basis of the National Cancer Institute’s Common Terminology Criteria for Adverse Events (ver. 4.0).
    Results: The 1-, 2-, and 3-year survival rates were 89.2% (95% confidence interval [CI], 74.5-95.9%),
    67.3% (95% CI, 50.7-80.4%), and 60.9% (95% CI, 44.1-75.4%), respectively. The median survival time was
    3.6 years. The median progression-free survival time was 8 months. Balloon increase (increased tumor stain
    under balloon occlusion; hazard ratio, 3.17; 95% CI, 1.135-11.201; P = 0.027) was the only factor significantly
    associated with overall survival on the multivariate analysis. No deaths occurred, but grade 2 cholecystitis
    requiring conservative treatment developed in 2 patients (4.8%). No adverse events over grade 3 occurred.
    Conclusion: B-TACE with miriplatin was associated with comparable tumor control and overall survival
    without severe adverse events in patients with HCC. Balloon increase was the only factor significantly associated
    with overall survival.

  • 第2回Interventional Radiology優秀論文賞

    2018.6   日本IVR学会   Interventional Radiology 2017; 2: 64-73 Comparison of the Local Control Effects of　Microballoon-Occluded Transarterial Chemoembolization　(TACE) Using Miriplatin and Using Epirubicin for　Hepatocellular Carcinoma: A Retrospective Study of 62 Cases

  • 第73回日本医学放射線学会総会CyPos賞

    2014.4   日本医学放射線学会   Comparison of the local control effects of microballoon-occluded transarterial chemoembolization (TACE) with miriplatin and TACE with epirubicin for hepatocellular carcinoma

    　More details

    OBJECTIVE
    This study aimed to compare the local control effects of microballoon-occluded transarterial chemoembolization (B-TACE) with miriplatin (MPT) and those of TACE with epirubicin (EPIR) for hepatocellular carcinoma (HCC).
    MATERIALS AND METHODS
    Fifty-five HCC cases were treated with TACE using EPIR or MPT. Thirty patients (20 men, 10 women; mean age, 74.4 years) were treated using B-TACE with MPT (the MPT-B-TACE group), and 25 patients (15 men, 10 women; mean age, 72.2 years) were treated using TACE with EPIR (the EPIR-TACE group). The local control rates (modified Response Evaluation Criteria in Solid Tumors [mRECIST]), time to treatment failures (Kaplan-Meier and log-rank tests), and adverse events (AEs) were evaluated.
    RESULTS
    There were no significant differences in gender, age, chronic liver disease etiology, Child-Pugh class, and tumor size between the groups. The tumor multiplicity rate of the EPIR-TACE group was higher than that of the MPT-B-TACE group. The overall AE incidence did not significantly differ between the groups. According to the mRECIST, the objective response rate including complete and partial responses, in the MPT-B-TACE group (90%) was significantly higher than that in the EPIR-TACE group (76%). Overall, local recurrences in the MPT-B-TACE group were significantly lower than in the EPIR-TACE group (p < 0.05). Excluding multiple HCC cases, the local recurrence rate in the MP T-B-TACE group was significantly lower than in the EPIR-TACE group (p < 0.05).
    CONCLUSION
    MPT-B-TACE was associated with a higher objective response rate and lower local recurrence rate than EPIR-TACE, and both showed similar adverse effects.

  • 平成23年度　日本医学放射線学会　優秀論文賞

    2012.4   社団法人　日本医学放射線学会   Performance of radiological methods in diagnosing hepatocellular carcinoma preoperatively in a recipient of living related liver transplantation: comparison with step section histopathology.

  • 第75回　日本薬理学会年会　年会優秀発表賞

    2002.3   日本薬理学会   ヒト臍帯静脈内皮の低浸透圧刺激感知機構におけるインテグリンの役割　

Papers

  • Radiology- and gene-based risk stratification in small renal cell carcinoma: A preliminary study Reviewed International journal

    Seiichiro Takao 1, Yasuhiro Ushijima 2, Yushi Motomura 1, Katsumi Sakamoto 1, Masakazu Hirakawa 1, Akihiro Nishie 3, Koshi Mimori 4, Yasuo Yamashita 5, Takashi Tsutsumi 6, Kousei Ishigami 2

    PLoS One   16 ( 9 )   2021.9

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Purpose: Most small renal cell carcinomas (small RCCs) will remain indolent after detection, but some stage I RCCs still metastasize. There are no risk-stratification imaging factors that could be used to identify poor-prognosis patients based on genomic profiling. Here, we evaluated the relationships between imaging parameters and RNA expressions in small RCC and attempted to identify imaging factors that could be used as effective biomarkers.

    Methods: We acquired biopsy specimens of 18 clear cell carcinomas that had undergone perfusion CT (pCT) and MRI between April 2018 and March 2019. We performed RNA sequencing, assessed RNA expressions, and calculated each tumor's cell-cycle progression (CCP) score, which has prognostic value in predicting metastatic progression. We classified the tumors into two groups: clear cell type A (ccA) and type B (ccB). CcA has better survival compared to ccB. We evaluated the following characteristics of each tumor: tumor size, presence of pseudocapsule, and fat. We used the pCT and MRI to measure each tumor's volume transfer constant (Ktrans), rate constant (Kep), extracellular extravascular volume fraction (VE), fractional plasma volume (VP), and apparent diffusion coefficient (ADC). The correlations between these small RCC imaging parameters and the tumor size and RNA expressions were determined.

    Results: The tumor size was significantly correlated with Kep and inversely correlated with VE, VP, ADC, and hallmark angiogenesis. The CCP score was significantly inversely correlated with Ktrans and Kep. The ccA tumors tended to show a pseudocapsule on MRI.

    Conclusion: Tumor size was correlated with low perfusion, but not with prognostic factors based on genomic profiling. Imaging parameters (e.g., Ktrans and Kep) and tumor characteristics (e.g., pseudocapsule) may enable gene-based risk stratification in small RCC.

    DOI： 10.1371/journal.pone.0256471

  • The Evolving Genomic Landscape of Esophageal Squamous Cell Carcinoma Under Chemoradiotherapy Reviewed International journal

    Hidenari Hirata Atsushi Niida , Nobuyuki Kakiuchi , Ryutaro Uchi , Keishi Sugimachi , Takaaki Masuda , Tomoko Saito , Shun-Ichiro Kageyama , Yushi Motomura , Shuhei Ito , Tadamasa Yoshitake , Daisuke Tsurumaru , Yusuke Nishimuta , Akira Yokoyama , Takanori Hasegawa , Kenichi Chiba , Yuichi Shiraishi , Junyan Du , Fumihito Miura , Masaru Morita , Yasushi Toh , Masakazu Hirakawa , Yoshiyuki Shioyama , Takashi Ito , Tetsuo Akimoto , Satoru Miyano , Tatsuhiro Shibata , Masaki Mori , Yutaka Suzuki , Seishi Ogawa , Kousei Ishigami , Koshi Mimori

    Cancer Research   81 ( 19 )   4926 - 4938   2021.8

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Esophageal squamous cell carcinoma (ESCC) often recurs after chemoradiotherapy, and the prognosis of ESCC after chemoradiotherapy has not improved over the past few decades. The mutation process in chemoradiotherapy-resistant clones and the functional relevance of genetic alterations remain unclear. To address these problems, we performed whole-exome sequencing of 52 tumor samples from 33 patients with ESCC who received radiotherapy combined with 5-fluorouracil/platinum. In multiregion analyses of pretreatment and locally recurrent lesions from five cases, most driver gene-altered clones remained under chemoradiotherapy selection pressure, while few driver gene alterations were acquired at recurrence. The mutation signatures of recurrent ESCC, including increased deletion frequency and platinum dose-dependent base substitution signatures, were substantially different from those of primary ESCC and reflected the iatrogenic impacts of chemoradiotherapy. Single-region analysis of 28 pretreatment tumors indicated that focal copy-number gain at the MYC locus was significantly associated with poor progression-free survival and overall survival after chemoradiotherapy. MYC gain remained throughout the chemoradiotherapy course and potentially contributes to intrinsic resistance to chemoradiotherapy. Consistent with these findings, MYC copy number and mRNA and protein levels in ESCC cell lines correlated positively with resistance to radiotherapy, and MYC knockdown improved sensitivity to radiotherapy. Overall, these data characterize the clonal evolution process induced by chemoradiotherapy and clinically relevant associations for genetic alterations in ESCC. These findings increase our understanding of therapeutic resistance and support the rationale for precision chemoradiotherapy. SIGNIFICANCE: Whole-exome sequencing reveals the genetic evolution of ESCC during chemoradiotherapy, highlighting MYC gain in pretreatment tumors as a potential marker of therapy resistance.

    DOI： 10.1158/0008-5472.CAN-21-0653

  • Portal Vein Stenting for Jejunal Variceal Bleeding after Recurrence of Pancreatic Adenocarcinoma: A Case Report and Review of the Literature Reviewed International journal

    Seiichiro Takao 1, Masakazu Hirakawa 1, Kazuki Takeishi 2, Yushi Motomura 1, Katsumi Sakamoto 1, Hajime Otsu 2, Yusuke Yonemura 2, Koshi Mimori 2, Kousei Ishigami 3

    Interventional Radiology   6 ( 2 )   44 - 50   2021.7

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    A 73-year-old woman with portal vein stenosis caused by tumor recurrence after pancreatoduodenectomy was treated with stent placement without embolization of the jejunal varix. Anticoagulation therapy using heparin followed by rivaroxaban was administered after the procedure. She continued to receive systemic chemotherapy as an outpatient. Neither restenosis nor stent thrombosis was observed after 7 months. Based on the presented case and literature review, portal vein stenting is an effective treatment option for jejunal variceal bleeding caused by malignant portal venous stricture after pancreaticoduodenectomy. Antithrombotic therapy following portal venous stenting is required to prevent stent thrombosis in the majority of cases, although it has a risk of inducing recurrent variceal bleeding. Adjunctive jejunal variceal embolization can possibly be omitted in selected cases to obtain sufficient portal-SMV flow reconstruction.

    DOI： 10.22575

  • Midterm Outcomes and Prognostic Factors of Patients Treated　Using Microballoon-Occluded Transarterial　Chemoembolization with Miriplatin:　A Retrospective Study of 37 Cases Reviewed International journal

    Masakazu Hirakawa1)2), Torahiko Yamanouchi2), Satoru Tsuruta3), Akihiro Inoue2), Hidenari Hirata1), Keiji Matsumoto1), Katsumi Sakamoto1), Hironori Sakai3), Koshi Mimori4), Hiroshi Honda5)

    Interventional Radiology   3   97 - 109   2018.6

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Purpose: This study aimed to retrospectively evaluate the overall survival and prognostic factors of patients
    treated using microballoon-occluded transarterial chemoembolization (B-TACE) with miriplatin for hepatocellular
    carcinoma (HCC).
    Materials and Methods: Thirty-seven patients (23 men and 14 women; mean age, 74.1 years; Barcelona
    Clinic Liver Cancer stage A:21, B:10, C:6; first TACE, 17) treated using B-TACE with miriplatin were retrospectively
    analyzed. Overall survival and progression-free survival were analyzed using Kaplan-Meier methods,
    and a multivariate analysis was performed to identify prognostic factors. Side effects were analyzed on
    the basis of the National Cancer Institute’s Common Terminology Criteria for Adverse Events (ver. 4.0).
    Results: The 1-, 2-, and 3-year survival rates were 89.2% (95% confidence interval [CI], 74.5-95.9%),
    67.3% (95% CI, 50.7-80.4%), and 60.9% (95% CI, 44.1-75.4%), respectively. The median survival time was
    3.6 years. The median progression-free survival time was 8 months. Balloon increase (increased tumor stain
    under balloon occlusion; hazard ratio, 3.17; 95% CI, 1.135-11.201; P = 0.027) was the only factor significantly
    associated with overall survival on the multivariate analysis. No deaths occurred, but grade 2 cholecystitis
    requiring conservative treatment developed in 2 patients (4.8%). No adverse events over grade 3 occurred.
    Conclusion: B-TACE with miriplatin was associated with comparable tumor control and overall survival
    without severe adverse events in patients with HCC. Balloon increase was the only factor significantly associated
    with overall survival.

  • Comparison of the Local Control Effects of Microballoon-Occluded Transarterial Chemoembolization (TACE) Using Miriplatin and Using Epirubicin for Hepatocellular Carcinoma: A Retrospective Study of 62 Cases Reviewed International journal

    Masakazu Hirakawa, Torahiko Yamanouchi, Satoru Tsuruta, Hidenari Hirata, Koushi Mimori, Hiroshi Honda

    Interventional Radiology   2   64 - 73   2017.6

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Purpose: This study aimed to retrospectively compare the local control and safety of microballoonoccluded
    transarterial chemoembolization (B-TACE) using miriplatin (MPT) and of conventional TACE (CTACE)
    using epirubicin (EPIR) for hepatocellular carcinoma (HCC).
    Materials and Methods: Thirty-nine patients (24 men, 15 women; mean age, 73.4 years) were treated using
    B-TACE with MPT (MPT-B-TACE group). As a historical comparison, 23 patients (13 men, 10 women;
    mean age, 72.2 years) who were treated using C-TACE with EPIR (EPIR-C-TACE group) were investigated.
    The therapeutic effect within 2 weeks after treatment was compared between the groups based on the Response
    Evaluation Criteria in Cancer of the Liver (RECICL), and time to local recurrence was compared
    based on the Kaplan-Meier method and log-rank tests. The side effects were compared based on the Common
    Terminology Criteria for Adverse Events (ver. 4.0).
    Results: No significant differences were noted in patients’ characteristics between the groups. The overall
    incidence of postembolization syndrome was significantly lower in the MPT-B-TACE group than in the
    EPIR-C-TACE group (p<0.05), but two cases in the MPT-B-TACE group developed grade 2 cholecystitis.
    Based on the RECICL, the objective response rate, including TE4 and TE3, within 2 weeks after treatment
    was significantly higher in the MPT-B-TACE group (89.7%) than in the EPIR-C-TACE group (78.3%). Overall,
    local recurrence was significantly less frequent in the MPT-B-TACE group than in the EPIR-C-TACE
    group (p=0.02).
    Conclusion: MPT-B-TACE was associated with a higher objective response rate and lower local recurrence
    rate than EPIR-C-TACE without a significant increase in adverse effects.

  • Decreased Expression of Fructose-1,6-bisphosphatase Associates with Glucose Metabolism and Tumor Progression in Hepatocellular Carcinoma. Reviewed International journal

    Hirata H, Sugimachi K, Komatsu H, Ueda M, Masuda T, Uchi R, Sakimura S, Nambara S, Saito T, Shinden Y, Iguchi T, Eguchi H, Ito S, Terashima K, Sakamoto K, Hirakawa M, Honda H, Mimori K.

    Cancer Res   76 ( 11 )   3265 - 3276   2016.6

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Fructose-1,6-bisphosphatase (FBP1), the rate-limiting enzyme in gluconeogenesis, is reduced in expression in certain cancers where it has been hypothesized to act as a tumor suppressor, including in hepatocellular carcinoma (HCC). Here, we report functional evidence supporting this hypothesis, providing a preclinical rationale to develop FBP1 as a therapeutic target for HCC treatment. Three independent cohorts totaling 594 cases of HCC were analyzed to address clinical significance. Lower FBP1 expression associated with advanced tumor stage, poor overall survival, and higher tumor recurrence rates. In HCC cell lines, where endogenous FBP1 expression is low, engineering its ectopic overexpression inhibited tumor growth and intracellular glucose uptake by reducing aerobic glycolysis. In patient specimens, promoter methylation and copy-number loss of FBP1 were independently associated with decreased FBP1 expression. Similarly, FBP1 downregulation in HCC cell lines was also associated with copy-number loss. HCC specimens exhibiting low expression of FBP1 had a highly malignant phenotype, including large tumor size, poor differentiation, impaired gluconeogenesis, and enhanced aerobic glycolysis. The effects of FBP1 expression on prognosis and glucose metabolism were confirmed by gene set enrichment analysis. Overall, our findings established that FBP1 downregulation in HCC contributed to tumor progression and poor prognosis by altering glucose metabolism, and they rationalize further study of FBP1 as a prognostic biomarker and therapeutic target in HCC patients.

  • Downregulation of PRRX1 Confers Cancer Stem Cell-Like Properties and Predicts Poor Prognosis in Hepatocellular Carcinoma. Reviewed International journal

    Hirata H, Sugimachi K, Takahashi Y,3, Ueda M, Sakimura S, Uchi R, Kurashige J, Takano Y, Nanbara S, Komatsu H, Saito T, Shinden Y, Iguchi T, Eguchi H, Atsumi K, Sakamoto K, Doi T, Hirakawa M, Honda H, Mimori K.

    Ann Surg Oncol.   3 ( S1 )   402 - 409   2015.12

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    BACKGROUND:
    Downregulation of paired related homeobox 1 (PRRX1) is associated with the acquisition of cancer stem cell (CSC)-like properties and poor prognosis in cancers. The purpose of this study is to clarify the role of PRRX1 expression in predicting prognosis and mediating CSC-like properties in hepatocellular carcinoma (HCC).

    METHODS:
    The association between PRRX1 expression and overall survival (OS) of patients with HCC was analyzed in three independent datasets: 62 resected primary cases, 242 cases from GSE14520, and 162 cases from The Cancer Genome Atlas (TCGA). A cell line expressing PRRX1 (HuH7) was established for the functional analyses. The ability to form spheres, the expression levels of the hepatic CSC surface markers (CD13, CD133, and EpCAM), in vitro chemosensitivity to 5-fluorouracil (FU), and radiosensitivity were evaluated.

    RESULTS:
    Univariate and multivariate analyses showed that the 5-year OS of the low PRRX1 expression group was significantly poorer than that of the high PRRX1 expression group (P = 0.024 and P = 0.045, respectively). Consistent with this, the low PRRX1 expression group in GSE14520 and TCGA datasets showed significantly shorter OS (P = 0.027 and P = 0.010, respectively). Gene set enrichment analysis on GSE14520 and TCGA datasets indicated that downregulation of PRRX1 was correlated with the stemness signature. The number of spheres and the expression levels of CSC markers were significantly decreased when PRRX1 was expressed. Moreover, PRRX1 impaired resistance to 5-FU and radiation.

    CONCLUSIONS:
    Downregulation of PRRX1 expression contributes to the poor prognosis of patients with HCC through acquisition of CSC-like properties.

  • Mitochondrial Transcription Factor A and Mitochondrial Genome as Molecular Targets for Cisplatin-Based Cancer Chemotherapy. Reviewed International journal

    Kohno K, Wang KY, Takahashi M, Kurita T, Yoshida Y, Hirakawa M, Harada Y, Kuma A, Izumi H, Matsumoto S

    Int J Mol Sci.   16 ( 8 )   19836 - 19850   2015.8

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Mitochondria are important cellular organelles that function as control centers of the energy supply for highly proliferative cancer cells and regulate apoptosis after cancer chemotherapy. Cisplatin is one of the most important chemotherapeutic agents and a key drug in therapeutic regimens for a broad range of solid tumors. Cisplatin may directly interact with mitochondria, which can induce apoptosis. The direct interactions between cisplatin and mitochondria may account for our understanding of the clinical activity of cisplatin and development of resistance. However, the basis for the roles of mitochondria under treatment with chemotherapy is poorly understood. In this review, we present novel aspects regarding the unique characteristics of the mitochondrial genome in relation to the use of platinum-based chemotherapy and describe our recent work demonstrating the importance of the mitochondrial transcription factor A (mtTFA) expression in cancer cells.

  • Transarterial chemoembolization for hepatocellular carcinoma using a new double-lumen microballoon catheter with a side hole. Reviewed International journal

    Wataru todoroki, Masakazu Hirakawa, Eiki nagao, Hiroyasu soeda, Satoru Tsuruta, Hiroshi Honda

    J Vasc Interv Radiol   25 ( 9 )   1485 - 1486   2014.9

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Efficacy of preoperative transcatheter arterial chemoembolization combined with systemic chemotherapy for treatment of unresectable hepatoblastoma in children. Reviewed International journal

    Masakazu Hirakawa, Akihiro Nishie, Asayama Yoshiki, Fujita Nobuhiro, Kousei Ishigami, Tatsuro Tajiri, tomoaki taguchi, Hiroshi Honda

    Jpn J Radiol.   32 ( 9 )   529 - 536   2014.9

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    PURPOSE:
    The purpose of this study was to evaluate, retrospectively, the clinical efficacy of preoperative transcatheter arterial chemoembolization (TACE) combined with systemic chemotherapy for unresectable hepatoblastoma.
    MATERIALS AND METHODS:
    Five boys and three girls (mean age 15.2 months) were treated with preoperative TACE combined with systemic chemotherapy for unresectable hepatoblastomas. Mean tumor diameter and mean alfa-fetoprotein (AFP) level were 11.8 cm and 549,386 ng/mL, respectively. Pretreatment, the extent of disease (PRETEXT) was: II, 1; III, 6; IV, 1. For all patients, preoperative systemic chemotherapy was administered before TACE. At each TACE, carboplatin and adriamycin mixed with iodized oil were infused into the feeding arteries. Tumor response and prognosis after treatment were evaluated.
    RESULTS:
    TACE resulted in few Grade 1 adverse effects (AEs), without G3 or more AEs, according to CTACAE 3.0. Mean tumor shrinkage was 60.9 %, and the mean AFP decrease from initial levels was 94.8 %. In all cases TACE combined with systemic chemotherapy enabled subsequent safe and complete surgical resection. After a mean follow-up of 59 months, tumor-free survival was 75 %.
    CONCLUSION:
    Preoperative TACE combined with systemic chemotherapy was effective in inducing surgical resectability of unresectable hepatoblastoma.

  • Prediction of outcome with FDG-PET in definitive chemoradiotherapy for esophageal cancer. Reviewed International journal

    Kazushige Atsumi, Katsumasa Nakamura, Koichiro Abe, Masakazu Hirakawa, Ohga Saiji, Shingo Baba, 磯田 拓郎, Hiroshi Honda

    J Radiat Res.   54 ( 8 )   890 - 898   2013.9

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Transcatheter arterial embolization for chest wall metastasis of hepatocellular carcinoma. Reviewed International journal

    Hirakawa Masakazu, Eiki Nagao, Hiroyasu Soeda, Satoru Tsuruta, Hironori Sakai, Honda Hiroshi

    World J Radiology   28 ( 5(2) )   45 - 48   2013.2

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Hemothorax due to rupture of metastatic hepatocellular carcinoma (HCC) is a very rare complication with high mortality because of uncontrollable hemorrhage. A 71-year-old man treated by transcatheter arterial embolization for HCC with massive bleeding from chest wall metastasis is reported. Enhanced computed tomography and selective intercostal angiogram showed a hypervascular mass in the right chest wall and extravasation of contrast agent. After successful transcatheter arterial embolization with gelatin sponge particles and metallic coils, the patient recovered from shock without major complication. To our knowledge, a successfully treated case of hemothorax due to rupture of metastatic HCC has not previously been described.

  • Clinical outcomes of symptomatic arterioportal fistulas after transcatheter arterial embolization. Reviewed International journal

    Hirakawa Masakazu, Nishie Akihiro, Yoshiki Asayama, Ishigami Kousei, Ushijima Yasuhiro, Nobuhiro Fujita, Honda Hiroshi

    World J Radiology   28 ( 5(2) )   33 - 44   2013.2

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    AIM:

    To evaluate the complications and clinical outcomes of transcatheter arterial embolization (TAE) for symptoms related to severe arterioportal fistulas (APFs).

    METHODS:

    Six patients (3 males, 3 females; mean age, 63.8 years; age range, 60-71 years) with chronic liver disease and severe APFs due to percutaneous intrahepatic treatment (n = 5) and portal vein (PV) tumor thrombosis of hepatocellular carcinoma (n = 1) underwent TAE for symptoms related to severe APFs [refractory ascites (n = 4), hemorrhoidal hemorrhage (n = 1), and hepatic encephalopathy (n = 1)]. Control of symptoms related to APFs and complications were evaluated during the follow-up period (range, 4-57 mo).

    RESULTS:

    In all patients, celiac angiography revealed immediate retrograde visualization of the main PV before TAE, indicating severe APF. Selective TAE for the hepatic arteries was performed using metallic coils (MC, n = 4) and both MCs and n-butyl cyanoacrylate (n = 2). Three patients underwent repeated TAEs for residual APFs and ascites. Four patients developed PV thrombosis after TAE. During the follow-up period after TAE, APF obliteration and symptomatic improvement were obtained in all patients.

    CONCLUSION:

    Although TAE for severe APFs may sometimes be complicated by PV thrombosis, TAE can be an effective treatment to improve clinical symptoms related to severe APFs.

  • Radiological findings as favorable predictors of pain relief in patients with osteoporotic compression fractures after percutaneous vertebroplasty: a retrospective study of 156 cases. Reviewed International journal

    Hirakawa M, Kobayashi N, Ishiyama M, Fuwa S, Saida Y, Honda H, Numaguchi Y.

    Jpn J Radiol. 2012 Feb 28.   2012.2

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Abstract

    PURPOSE:

    We evaluated the relationships between pre-procedural radiological findings and short-term pain relief in patients with osteoporotic compression fractures after percutaneous vertebroplasty (PVP).

    MATERIALS AND METHODS:

    A retrospective review of pre-procedural radiological images of 156 patients with painful osteoporotic compression fracture was performed. Pain was measured with a visual analogue scale (VAS). Complete pain relief was defined as a VAS pain score of 0 or 1 at 3 months after PVP. Statistical analyses were conducted to evaluate the relationship between the pre-procedural imaging factors and pain relief using Pearson's chi-squared test. Multivariate logistic regression analysis was also performed.

    RESULTS:

    Complete pain relief was obtained in 45.5% of patients. An intravertebral cleft larger than half the height of the fractured vertebral body (FVB) was a significant key factor in the complete pain relief group after 3 months. Further, ≥40% of the spinal canal occupied by bony fragments of the FVB was related to incomplete pain relief.

    CONCLUSION:

    A large intravertebral cleft was a favorable short-term outcome predictor in patients with osteoporotic compression fractures after PVP, while severe protrusion of the FVB causing lumbar spinal canal stenosis was not a favorable short-term outcome predictor of complete pain relief.

  • Performance of radiological methods in diagnosing hepatocellular carcinoma preoperatively in a recipient of living related liver transplantation: comparison with step section histopathology Reviewed International journal

    Masakazu Hirakawa, Kengo Yoshimitsu, Hiroyuki Irie, Tsuyoshi Tajima, Akihiro Nishie, Yoshiki Asayayama, Kousei Ishigami, Daisuke Kakihara, Akinobu Taketomi, Shin-ichi Aishima and Hiroshi Honda

    Jpn J Radiol   29 ( 2 )   2011.2

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • MR prediction of postnatal outcomes in left-sided congenital diaphragmatic hernia using right lung signal intensity: comparison with that using right lung volume. Reviewed International journal

    Nishie A, Tajima T, Asayama Y, Ishigami K, Hirakawa M, Nakayama T, Ushijima Y, Kakihara D, Okamoto D, Yoshiura T, Masumoto K, Taguchi T, Tsukimori K, Tokunaga S, Irie H, Yoshimitsu K, Honda H.

    J Magn Reson Imaging   30 ( 1 )   2009.7

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Uterine artery embolization along with the administration of methotrexate for cervical ectopic pregnancy: technical and clinical outcomes. Reviewed International journal

    Hirakawa M, Tajima T, Yoshimitsu K, Irie H, Ishigami K, Yahata H, Wake N, Honda H.

    AJR Am J Roentgenol. 2009 Jun   192 ( 6 )   2009.6

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Protein kinase A inhibits lysophosphatidic acid-induced migration of airway smooth muscle cells. Reviewed International journal

    Hirakawa M, Karashima Y, Watanabe M, Kimura C, Ito Y, Oike M.

    J Pharmacol Exp Ther. 2007 Jun;321(3):1102-8. Epub 2007 Mar 8.   2007.6

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Pivotal role of integrin alpha5beta1 in hypotonic stress-induced responses of human endothelium. Reviewed International journal

    Hirakawa M, Oike M, Watanabe M, Karashima Y, Ito Y.

    FASEB J. 2006 Oct;20(12):1992-9.   2006.10

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Tumor cell apoptosis by irradiation-induced nitric oxide production in vascular endothelium Reviewed International journal

    Hirakawa M, Oike M, Masuda K, Ito Y.

    Cancer Res. 2002 Mar 1;62(5):1450-7.   62 ( 5 )   1450 - 1457   2002.5

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Esophageal lymphangioma: Endoscopic ultrasound, computed tomography, and magnetic resonance imaging appearance

    Nanjo K., Tsurumaru D., Hirakawa M., Nishimuta Y., Mimori K., Ishigami K.

    Radiology Case Reports   19 ( 11 )   4841 - 4844   2024.11   （ ISSN:1930-0433 ）

    　More details

    Language：English   Publisher：Radiology Case Reports  

    A case of esophageal lymphangioma in a 75-year-old man who complained of worsening dysphagia is presented. Endoscopic ultrasound showed an echogenic pattern of honeycomb or grid-like multiple microcysts within the submucosa. The sagittal image of computed tomography showed a thickened esophageal wall and fluid retention in the proximal esophageal lumen. Magnetic resonance imaging showed a high signal intensity mass with a septate-like internal structure on T2-weighted imaging and short tau inversion recovery. The tumor was completely resected by endoscopic submucosal dissection. Esophageal lymphangioma is a rare submucosal tumor that can be precisely diagnosed by CT and/or MRI.

    DOI： 10.1016/j.radcr.2024.07.144

    Scopus

    PubMed

  • A rare case of liver regenerative and non-neoplastic lesion resembling a well-differentiated hepatocellular carcinoma

    Hirose, K; Toshima, T; Tobo, T; Kai, S; Hirakawa, M; Higuchi, S; Ofuchi, T; Hosoda, K; Yonemura, Y; Hisamatsu, Y; Masuda, T; Aishima, S; Mimori, K

    SURGICAL CASE REPORTS   10 ( 1 )   30   2024.2   （ ISSN:2198-7793 ）

    　More details

  • 高分化型肝細胞癌との鑑別に苦慮した肝再生性非腫瘍性病変の稀な1例(A rare case of liver regenerative and non-neoplastic lesion resembling a well-differentiated hepatocellular carcinoma)

    Hirose Kosuke, Toshima Takeo, Tobo Taro, Kai Satohiro, Hirakawa Masakazu, Higuchi Satoshi, Ofuchi Takashi, Hosoda Kiyotaka, Yonemura Yusuke, Hisamatsu Yuichi, Masuda Takaaki, Aishima Shinichi, Mimori Koshi

    Surgical Case Reports   10   1 of 6 - 6 of 6   2024.2

    　More details

    Language：English   Publisher：Springer Berlin Heidelberg  

    49歳男性。特に既往や家族歴、飲酒歴、ウイルス感染歴などなかった。定期検診の腹部超音波検査で肝S7/8に2cm径の腫瘍および軽度の脂肪肝を伴う低エコー病変が認められた。単純CTでは高吸収域を示した。MRIでは、腫瘍はT1強調画像で境界部に高信号、内部に低信号を呈し、T2強調画像では低信号を示した。Gd-EOB-DTPA造影MRIでは、病変に脂肪が含まれており、EOB取り込みも認められた。以上より高分化型肝細胞癌(HCC)を疑い、腹腔鏡下S7/8部分切除術を施行した。患者は術後10日目に合併症なく退院した。病理組織検査の結果、過形成性病変や腺腫などの腫瘍性病変は認められず、肝小葉壊死を伴う再生性肝変化と診断した。

  • Dosimetry of Occupational Eye Lens Dose Using a Novel Direct Eye Dosimeter, DOSIRIS, during Interventional Radiology Procedures

    Hirakawa Masakazu, Nakatake Hiroshi, Tsuruta Satoru, Matsuura Shuji, Motomura Yuushi, Hiraki Yoshiki, Mimori Koshi, Ishigami Kousei

    Interventional Radiology   7 ( 2 )   40 - 43   2022.7   （ eISSN:24320935 ）

    　More details

    Language：English   Publisher：Japanese Society of Interventional Radiology  

    <p>In response to the recommendation by the International Commission on Radiological Protection to lower the equivalent eye dose limit, the Japanese Government in April 2021 lowered the equivalent dose limit for the eye lens for occupational exposure. A considerable number of interventional radiology operators are exposed to levels above the new limit. For this reason, a need exists to more accurately evaluate eye lens dose in interventional radiology operators by using a novel direct eye dosimeter, the DOSIRIS™ (IRSN, France), which is capable of measuring a 3-mm dose equivalent under protective glasses. The DOSIRIS is a thermoluminescent dosimeter that exhibits good energy dependence and better directional properties than other dosimeters. Dosimetry using DOSIRIS might be accurate and compatible with the latest regulations.</p>

    DOI： 10.22575/interventionalradiology.2022-0005

    Web of Science

    PubMed

    CiNii Research

  • Phase I clinical trial of a five-peptide cancer vaccine combined with cyclophosphamide in advanced solid tumors. Reviewed International journal

    Murahashi M, Hijikata Y, Yamada K, Tanaka Y, Kishimoto J, Inoue H, Marumoto T, Takahashi A, Okazaki T, Takeda K, Hirakawa M, Fujii H, Okano S, Morita M, Baba E, Mizumoto K, Maehara Y, Tanaka M, Akashi K, Nakanishi Y, Yoshida K, Tsunoda T, Tamura K, Nakamura Y, Tani K.

    166   45 - 58   2016.5

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    We designed a phase I trial to investigate the safety, immune responses and clinical benefits of a five-peptide cancer vaccine in combination with chemotherapy. Study subjects were patients positive for HLA-A2402 with locally advanced, metastatic, and/or recurrent gastrointestinal, lung or cervical cancer. Eighteen patients including nine cases of colorectal cancer were treated with escalating doses of cyclophosphamide 4days before vaccination. Five HLA-A2402-restricted, tumor-associated antigen (TAA) epitope peptides from KOC1, TTK, URLC10, DEPDC1 and MPHOSPH1 were injected weekly for 4weeks. Treatment was well tolerated without any adverse events above grade 3. Analysis of peripheral blood lymphocytes showed that the number of regulatory T cells dropped from baseline after administration of cyclophosphamide and confirmed that TAA-specific T cell responses were associated significantly with longer overall survival. This phase I clinical trial demonstrated safety and promising immune responses that correlated with vaccine-induced T-cell responses. Therefore, this approach warrants further clinical studies.

  • A case of gastric plexiform fibromyxoma: radiological and pathological findings. Reviewed International journal

    Katsumi Sakamoto, Masakazu Hirakawa, Kazushige Atsumi, Koshi Mimori, Shibata Kohei, Taro Tobo, Hidetaka Yamamoto, Hiroshi Honda

    Jpn J Radiol.   32 ( 7 )   431 - 436   2014.7

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Plexiform fibromyxoma is a relatively new pathological category that consists of a rare group of non-gastrointestinal stromal tumors with a peculiar plexiform growth pattern. We report a case of gastric plexiform fibromyxoma in a 60-year-old man. Gastroscopic examination revealed a gastric submucosal tumor in the antrum. Magnetic resonance imaging (MRI) showed a nodule with distinct signal hyperintensity on T2-weighted images, with strong enhancement peripherally in the early phase to the entire lesion in the delayed phase. Endoscopic ultrasound-guided fine-needle aspiration cytology was performed, and the cytological diagnosis was spindle cell tumor, so partial gastrectomy was performed under a preoperative diagnosis of GIST. The resected tumor demonstrated plexiform architecture, myxoid stroma, prominent vasculature, and spindle cells, reflecting the characteristic findings on MRI. This is the first report to describe radiological findings for gastric plexiform fibromyxoma.

  • Image quality of Gd-EOB-DTPA-enhanced magnetic resonance imaging of the liver using dual-source parallel radiofrequency transmission technology: Comparison with the post-processing correction method for B1 inhomogeneity-induced signal loss. Reviewed International journal

    Hirakawa Masakazu, Nishie Akihiro, Yoshiki Asayama, Honda Hiroshi, Yoshiura Takashi

    Eur J Radiol   81 ( 11 )   3035 - 3040   2012.11

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Image quality of Gd-EOB-DTPA-enhanced magnetic resonance imaging of the liver using dual-source parallel radiofrequency transmission technology: Comparison with the post-processing correction method for B1 inhomogeneity-induced signal loss. Reviewed International journal

    Takayama Y, Nishie A, Asayama Y, Ishigami K, Kakihara D, Nakayama T, Yoshiura T, Obara M, Hirakawa M, Honda H.

    Eur J Radiol.   2012.5

    　More details

    Publishing type：Research paper (scientific journal)  

  • Radiological catheter placement for transcatheter arterial steroid injection therapy to treat severe acute hepatic failure: technical feasibility and efficacy. Reviewed International journal

    Ushijima Y, Tajima T, Yoshimitsu K, Irie H, Nishie A, Hirakawa M, Ishigami K, Okamoto D, Kotoh K, Honda H.

    Acta Radiol. 2012   1 ( 53(2): )   2012.3

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Enhancement pattern analysis of hypervascular hepatocellular carcinoma on dynamic MR imaging with histopathological correlation: Validity of portal phase imaging for predicting tumor grade. Reviewed International journal

    Okamoto D, Yoshimitsu K, Nishie A, Tajima T, Asayama Y, Ishigami K, Hirakawa M, Ushijima Y, Kakihara D, Nakayama T, Nishihara Y, Aishima S, Taketomi A, Kishimoto J, Honda H.

    Eur J Radiol.   2011.3

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • The endoscopic diagnosis of nonerosive reflux disease using flexible spectral imaging color enhancement image: a feasibility trial Reviewed International journal

    M. Miyasaka, M. Hirakawa, K. Nakamura, F. Tanaka, K. Mimori, M. Mori, H. Honda

    Diseases of the Esophagus   2011.3

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Radiological assessment of hepatic vein invasion by hepatocellular carcinoma using combined computed tomography hepatic arteriography and computed tomography arterial portography. Reviewed International journal

    Nishie A, Tajima T, Asayama Y, Ishigami K, Hirakawa M, Ushijima Y, Kakihara D, Okamoto D, Fujita N, Taketomi A, Yoshimitsu K, Honda H.

    Jpn J Radiol.   28 ( 6 )   2010.7

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Recanalization of splenic artery aneurysm after transcatheter arterial embolization using N-butyl cyanoacrylate. Reviewed International journal

    Matsumoto K, Ushijima Y, Tajima T, Nishie A, Hirakawa M, Ishigami K, Yamaji Y, Honda H.

    Cardiovasc Intervent Radiol   33 ( 1 )   2010.2

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Detection of hepatocellular carcinoma (HCC) using super paramagnetic iron oxide (SPIO)-enhanced MRI: Added value of diffusion-weighted imaging (DWI). Reviewed International journal

    Nishie A, Tajima T, Ishigami K, Ushijima Y, Okamoto D, Hirakawa M, Nishihara Y, Taketomi A, Hatakenaka M, Irie H, Yoshimitsu K, Honda H.

    J Magn Reson Imaging   31 ( 2 )   2010.2

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 2010 Feb

  • Lesions arising in or involving the iliopsoas groove. Reviewed International journal

    Ishigami K, Yoshimitsu K, Irie H, Tajima T, Asayama Y, Nishie A, Hirakawa M, Ushijima Y, Okamoto D, Honda H.

    J Comput Assist Tomogr.   2008.11

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Significance of perivascular soft tissue around the common hepatic and proximal superior mesenteric arteries arising after pancreaticoduodenectomy: evaluation with serial MDCT studies. Reviewed International journal

    Ishigami K, Yoshimitsu K, Irie H, Tajima T, Asayama Y, Hirakawa M, Kakihara D, Shioyama Y, Nishihara Y, Yamaguchi K, Honda H.

    Abdom Imaging.   2008.11

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • CT-guided radiofrequency ablation for osteoid osteoma Reviewed

    Nomoto A, Hirakawa M, Yoshimitsu K, Irie H, Tajima T, Nishie A, Ishimgami K, Ushijima Y, Okamoto D, Yamada I, Honda H.

    Fukuoka Igaku Zasshi.   2008.10

    　More details

    Language：Japanese   Publishing type：Research paper (scientific journal)  

  • Noninvasive estimation of hepatic steatosis using plain CT vs. chemical-shift MR imaging: significance for living donors. Reviewed International journal

    Yoshimitsu K, Kuroda Y, Nakamuta M, Taketomi A, Irie H, Tajima T, Hirakawa M, Ishigami K, Ushijima Y, Yamada T, Honda H.

    J Magn Reson Imaging.   2008.9

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Percutaneous transfemoral hepatic arterial infusion catheter placement with the use of a downsized coaxial catheter system: technical feasibility study. Reviewed International journal

    Tajima T, Yoshimitsu K, Irie H, Nishie A, Hirakawa M, Ishigami K, Ushijima Y, Okamoto D, Kida M, Kurogi R, Honda H, Kuroiwa T.

    J Vasc Interv Radiol.   2008.8

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Retroperitoneal well-differentiated inflammatory liposarcoma: a diagnostic dilemma. Reviewed International journal

    Kawano R, Nishie A, Yoshimitsu K, Irie H, Tajima T, Hirakawa M, Ishigami K, Ushijima Y, Okamoto D, Yabuuchi H, Taketomi A, Nishihara Y, Fujita N, Honda H.

    Radiat Med.   2008.8

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Microballoon occlusion test to predict colonic ischemia after transcatheter embolization of a ruptured aneurysm of the middle colic artery. Reviewed International journal

    Tajima T, Yoshimitsu K, Inokuchi H, Irie H, Nishie A, Hirakawa M, Ishigami K, Ushijima Y, Okamoto D, Honda H, Itoh H, Morita M, Kakeji Y.

    Cardiovasc Intervent Radiol.   2008.8

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Hemorrhagic mesenteric cystic lymphangioma presenting with acute lower abdominal pain: the diagnostic clues on MR Imaging. Reviewed International journal

    Okamoto D, Ishigami K, Yoshimitsu K, Irie H, Tajima T, Nishie A, Hirakawa M, Ushijima Y, Nishihara Y, Kakeji Y, Honda H.

    Emerg Radiol.   2008.7

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Radiological detectability of minute hepatic venous invasion in hepatocellular carcinoma. Reviewed International journal

    Nishie A, Yoshimitsu K, Irie H, Tajima T, Hirakawa M, Ishigami K, Ushijima Y, Okamoto D, Nishihara Y, Taketomi A, Honda H.

    Eur J Radiol.   2008.4

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Usefulness of apparent diffusion coefficient map in diagnosing prostate carcinoma: correlation with stepwise histopathology. Reviewed International journal

    Yoshimitsu K, Kiyoshima K, Irie H, Tajima T, Asayama Y, Hirakawa M, Ishigami K, Naito S, Honda H.

    J Magn Reson Imaging.   2008.1

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Radiologic detectability of minute portal venous invasion in hepatocellular carcinoma. Reviewed International journal

    Nishie A, Yoshimitsu K, Asayama Y, Irie H, Tajima T, Hirakawa M, Ishigami K, Nakayama T, Kakihara D, Nishihara Y, Taketomi A, Honda H.

    AJR Am J Roentgenol.   2008.1

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Detection of the gonadal veins in the diagnosis of transposed ovaries in patients with cervical carcinoma: a useful sign on MDCT. Reviewed International journal

    Hirakawa M, Yoshimitsu K, Kakihara D, Irie H, Asayayama Y, Ishigami K, Honda H.

    AJR Am J Roentgenol. 2007 Jun;188(6):1564-7.   2007.6

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Significance of mesenteric lymphadenopathy after pancreaticoduodenectomy for periampullary carcinomas: evaluation with serial MDCT studies. Reviewed International journal

    Ishigami K, Yoshimitsu K, Irie H, Tajima T, Asayama Y, Hirakawa M, Kakihara D, Shioyama Y, Nishihara Y, Yamaguchi K, Honda H.

    Eur J Radiol.   2007.5

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Arterial steroid injection therapy can inhibit the progression of severe acute hepatic failure toward fulminant liver failure. Reviewed International journal

    Kotoh K, Enjoji M, Nakamuta M, Yoshimoto T, Kohjima M, Morizono S, Yamashita S, Horikawa Y, Yoshimitsu K, Tajima T, Asayama Y, Ishigami K, Hirakawa M.

    World J Gastroenterol.   2006.11

    　More details

    Publishing type：Research paper (scientific journal)  

  • Accessory left gastric artery from left hepatic artery shown on MDCT and conventional angiography: correlation with CT hepatic arteriography. Reviewed International journal

    Ishigami K, Yoshimitsu K, Irie H, Tajima T, Asayama Y, Hirakawa M, Honda H.

    AJR Am J Roentgenol.   2006.10

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Hepatocellular carcinoma with a prominent vascular scar in the center: MR imaging findings. Reviewed International journal

    Yamauchi M, Asayama Y, Yoshimitsu K, Irie H, Tajima T, Hirakawa M, Ishigami K, Nakayama T, Kakihara D, Yamaguchi K, Nishihara Y, Aishima S, Honda H.

    Radiat Med.   2006.7

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Papillary renal carcinoma: diagnostic approach by chemical shift gradient-echo and echo-planar MR imaging. Reviewed International journal

    Yoshimitsu K, Kakihara D, Irie H, Tajima T, Nishie A, Asayama Y, Hirakawa M, Nakayama T, Naito S, Honda H.

    J Magn Reson Imaging.   2006.5

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Delayed-phase dynamic CT enhancement as a prognostic factor for mass-forming intrahepatic cholangiocarcinoma. Reviewed International journal

    Asayama Y, Yoshimitsu K, Irie H, Tajima T, Nishie A, Hirakawa M, Nakayama T, Kakihara D, Taketomi A, Aishima S, Honda H.

    Radiology.   2006.1

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Excess l-arginine restores endothelium-dependent relaxation impaired by monocrotaline pyrrole. Reviewed International journal

    Cheng W, Oike M, Hirakawa M, Ohnaka K, Koyama T, Ito Y.

    Toxicol Appl Pharmacol.   207 ( 3 )   187 - 194   2005.9

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1016/j.taap.2005.01.002

  • Steroid-induced osteonecrosis in refractory ulcerative colitis. Reviewed

    Ito K, Inuo-Nakayama M, Matsumoto M, Kubokawa M, Sadamoto Y, Kubo H, Tanaka M, Harada N, Torigoshi K, Hirakawa M, Nawata H.

    Fukuoka Igaku Zasshi.   2005.1

    　More details

    Language：Japanese   Publishing type：Research paper (scientific journal)  

  • MR imaging of renal cell carcinoma: its role in determining cell type. Reviewed International journal

    Yoshimitsu K, Irie H, Tajima T, Nishie A, Asayama Y, Hirakawa M, Nakayama T, Kakihara D, Honda H.

    Radiat Med.   2004.11

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Sequential activation of RhoA and FAK/paxillin leads to ATP release and actin reorganization in human endothelium Reviewed International journal

    Hirakawa M, Oike M, Karashima Y, Ito Y.

    J Physiol. 2004 Jul 15;558(Pt 2):479-88.   558 ( 2 )   479 - 488   2004.5

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1113/j.physiol.2004.065334

  • Preoperative intraarterial infusion chemotherapy for advanced gastric cancer--a retrospective review of four cases. International journal

    Iida T, Hirata N, Hirakawa M, Noguchi T.

    Radiat Med.   2003.8

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Theophylline and cAMP inhibit lysophosphatidic acid-induced hyperresponsiveness of bovine tracheal smooth muscle cells. Reviewed International journal

    Sakai J, Oike M, Hirakawa M, Ito Y.

    J Physiol. 2003 May 15;549(Pt 1):171-80   549 ( 1 )   171 - 180   2003.4

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    DOI： 10.1113/jphysiol.2003.039024

▼display all

Books

  • 肝癌診療ガイドライン2021年版

    平川雅和（Role：Joint author）

    一般社団法人　日本肝臓学会  2022.10 

    　More details

    Language：Japanese   Book type：Scholarly book

  • 画像診断ガイドライン　2021年版

    平川雅和（Role：Joint author）

    日本医学放射線学会  2021.9 

    　More details

    Language：Japanese   Book type：Scholarly book

  • RadFan特集　IVRにおける被ばく低減の試み　「晶体専用線量計DOSIRISによるIVR手技中水晶体被ばく線量測定」

    平川雅和（Role：Sole author）

    メディカルアイ  2019.6 

    　More details

    Responsible for pages：Vol.17.No９P68-71   Language：Japanese   Book type：Scholarly book

    Radiation-induced cataracts secondary to occupational exposure represent a recently recognized entity. Recent study reported that occupational eye doses from Interventional radiological procedures have the potential to exceed the new International Commission on Radiological Protection (ICRP) equivalent dose limit 20 mSv/year, particularly if no eye lens protective equipment is always used. Therefore, it is essential to evaluate the occupational eye dose and eye protection. DOSIRIS™ can estimate the 3mm dose-equivalent (Hp(3)), and it can be stuck just lateral to the left eye under lead glass. In this article, we introduce the fundamental characteristics of the DOSIRIS™ and report recent monitoring occupational eye doses estimated using DOSIRIS™ during TACE for HCC.

  • INNERVISION RSNA2018　特集　IVRの最新動向

    平川雅和（Role：Sole author）

    株式会社インナービジョン  2019.2 

    　More details

    Responsible for pages：第34巻第2号　P29   Language：Japanese   Book type：Scholarly book

  • INNERVISION RSNA2017　エキスパートによるRSNAベストレポート　IVR

    平川雅和（Role：Joint author）

    2018.2 

    　More details

    Language：Japanese   Book type：Scholarly book

  • 日本インターベンショナルラジオロジー学会雑誌　2017Vol.32.No4　IVRの被ばくup-to-data 「IVRの患者被ばく防護」

    平川雅和（Role：Sole author）

    日本インターベンショナルラジオロジー学会  2017.12 

    　More details

    Responsible for pages：Vol.32.No4　P9-13   Language：Japanese   Book type：Scholarly book

    Recent technologic innovations in interventional radiology (IVR) might produce better images quality with lower radiation doses, however, the widespread use of increasingly complex IVR procedures may still result in significant radiation exposure to both the patient and the operator. In this article, we present recommended guidelines, measurement of patients’ radiation dose and previous reports regarding patients’ radiation dose in recent IVR procedures including our dose reduction trial during DEB-TACE for HCC to obtain and refresh the information needed to understand the importance of dose reduction trial and the risks of recent IVR procedures.

  • 肝癌診療ガイドライン2017年版

    平川雅和（Role：Joint author）

    2017.10 

    　More details

    Language：Japanese   Book type：Scholarly book

  • 画像診断ガイドライン2016年版　消化器

    平川雅和（Role：Joint author）

    2016.8 

    　More details

    Language：Japanese   Book type：Scholarly book

  • Key所見からよむ　肝胆膵脾画像診断　肝臓編

    平川雅和（Role：Joint author）

    2016.2 

    　More details

    Language：Japanese  

  • 月刊新医療 特別企画　ここまで進んでいる、今のマンモグラフィ トモシンセシス機能搭載マンモグラフィ導入効果

    平川雅和,新田吉陽,三森功士（Role：Joint author）

    東京  2015.1 

    　More details

    Language：Japanese   Book type：Scholarly book

  • 画像診断ガイドライン

    平川 雅和（Role：Joint author）

    金原出版株式会社  2013.7 

    　More details

    Responsible for pages：CQ62　233-235   Language：Japanese   Book type：Scholarly book

    日本医学放射線学会の画像診断ガイドラインの消化器　肝細胞癌担当

  • 脊椎圧迫骨折に対する骨セメント治療：　経皮的椎体形成術

    平川雅和（Role：Sole author）

    別府市医師会  2010.7 

    　More details

    Responsible for pages：別府市医師会報　第41巻　第3号　平成22年夏季号45-46.   Book type：General book, introductory book for general audience

  • Clinical Challenge　問題・解答・解説　｢慢性膵炎に合併した自己免疫性膵炎｣ 消化器画像　2007第9巻4号　314-5,　5号　510-513

    平川雅和、本田浩

    2007.9 

    　More details

    Responsible for pages：消化器画像　2007第9巻4号　314-5,　5号　510-513   Language：Japanese   Book type：Scholarly book

  • 日独医報　臓器特異性MRI造影剤による画像診断へのインパクト：この後の展望も含めて

    吉満研吾, 中山智博,　柿原大輔, 入江裕之,田嶋強, 浅山良樹, 西江昭弘, 平川雅和, 石神康生,, 本田浩（Role：Joint author）

    2005.5 

    　More details

    Responsible for pages：50（3）：518-529   Language：Japanese   Book type：Scholarly book

▼display all

Presentations

  • Clinical Evaluation of a Radio-Protective Glove for Finger Exposure of Interventional Radiologist: A short-term study International conference

    Masakazu Hirakawa, S Kai, Y Hiraki, Y Motomura

    The 83rd Annual Meeting of the Japan Radiological Society  2024.4 

    　More details

    Event date： 2024.4

    Language：English  

    Venue：Yokohama   Country：Japan  

    Objectives: The purpose of this study was to evaluate the shielding effect of a novel tungsten-containing glove during interventional radiology.
    Methods: A total of 29 interventional radiological procedures performed by single operator were studied over the 3-month period. To measure the skin dose equivalent to the finger of operator and investigate the shielding effect of Radio-Protective Glove, radiophotoluminescent glass ring dosimeters (RPRD, Hp(0.07)) were placed at the middle and ring fingers of the left hand, with and without tungsten-containing rubber shielding, respectively. Additionally, to compare the skin dose equivalent of neck and finger, radiophotoluminescent glass dosimeters (RPGD Hp(10) and Hp(0.07)) and personal pocket dosimeter (real-time dosimeter, Hp(10)) were worn on neck over neck lead guard.
    Results: The average radiation exposure dose per month was 0.45 mSv, 1.33 mSv, 1.7 mSv and 3.03 mSv, personal pocket dosimeter, RPGD at neck, RPRD at middle finger with shielding and RPRD at ring finger without shielding, respectively. The skin dose equivalent of finger was higher than skin dose of neck. The skin dose equivalent for the finger exposure was reduced by approximately 44% using the Radio-Protective Glove. Conclusions: Novel tungsten-containing glove had excellent radiation shielding ability against x rays. The skin dose equivalent of neck was underestimated compared to finger dose. The skin dose equivalent of finger might not exceed the annual skin dose limit (500mSv), however, ring dosimeter at finger and Radio-Protective Glove might be necessary, especially in high volume center of interventional radiology.

  • DRL in JAPAN　and Radiation Dose Optimization Invited International conference

    M. Hirakawa

    60th RCRT-RST Annual Scientific Meeting  2024.2 

    　More details

    Event date： 2024.2

    Language：English   Presentation type：Oral presentation (general)  

    Venue：Bangkok   Country：Thailand  

  • HCCに対するTACE時のガラスバッジと水晶体専用線量計ドジリスによる術者の水晶体被ばく線量に関する検討

    平川雅和, 池俊浩, 松浦秀司

    第42回九州IVR研究会  2019.12 

    　More details

    Event date： 2019.12

    Language：Japanese  

    Venue：福岡   Country：Japan  

  • Combined conventional and microballoon-occluded TACE for HCC

    平川雅和

    Trans Arterial Ablation  2021.5 

    　More details

    Event date： 2019.10

    Language：Japanese   Presentation type：Symposium, workshop panel (public)  

    Venue：徳島   Country：Japan  

  • Comparison of microballoon-occluded TACE versus DEB-TACE for the treatment of patients with large and intermediate-stage HCCs International conference

    #M Hirakawa, Y Kikuchi , A Inoue , S Tsuruta, H Sakai, #K Mimori

    CIRSE 2019  2019.9 

    　More details

    Event date： 2019.9

    Language：English  

    Venue：Barcelona   Country：Spain  

    OBJECTIVE:
    Recently, microballoon-occluded transarterial chemoembolization (B-TACE) was developed in Japan, B-TACE induce dense lipidol accumulation in targeted hepatocellular carcinomas (HCCs) nodules. However, to the best of our knowledge, no comparison study has yet analyzed outcomes after B-TACE and TACE with drug-eluting-bead (DEB-TACE) in patients with HCC. The purpose of this study is to evaluate the efficacy and safety associated with B-TACE versus DEB-TACE for large (maximal diameter > 5 cm) and intermediate-stage HCCs.
    MATERIALS AND METHODS:
    This retrospective study involved naïve 35 patients with large and intermediate-stage HCCs who underwent B-TACE (n = 18) or DEB-TACE (n = 17) between April 2013 and May 2016. The decision between B-TACE and DEB-TACE was based on patient choice. Local control of largest tumor 3months after TACE, overall survival (OS) and adverse events (AEs) were compared between the two groups.
    RESULTS:
    The median duration of follow-up was 19 months (range, 8-48 months). Objective response rate analyzed with modified Response Evaluation Criteria in Solid Tumors (RECIST) was 38.9% after B-TACE and 52.9% after DEB-TACE (P = 0.039). No significant differences could be detected between the B-TACE and DEB-TACE groups with regard to median OS analyzed with the Kaplan-Meier method (28 versus 30 months, respectively; p=0.08). The 1-, 2-, and 3-year OS rates were 72.2, 62.4, and 42.8%, respectively, for the B-TACE and 82.4, 50.2, and 31.4%, respectively, for the DEB-TACE group. Hepatic dysfunction of grade 3 related DEB-TACE occurred in one patient and rate of AEs after DEB-TACE tended to be higher than B-TACE.
    CONTCLUSION:
    For the treatment of patients with large and intermediate-stage HCCs, DEB-TACE provided better tumor responses in comparison with B-TACE, which in turn DEB-TACE did not seem to improve survival in comparison with B-TACE.

  • ミリプラチン使用B-TACEとDEB-TACE治療法選択に関する検討

    M Hirakawa, Y Kikuchi , A Inoue , S Tsuruta, H Sakai, K Mimori

    第55回日本肝癌研究会  2019.7 

    　More details

    Event date： 2019.7

    Language：Japanese   Presentation type：Symposium, workshop panel (public)  

    Venue：東京   Country：Japan  

    ミリプラチンはC-TACEにおいて、その粘調度の高さから、十分な注入が困難で、塞栓不足等による高頻度の局所再発が報告されている。B-TACEは、引き込み効果や押し込み効果により、ミリプラチン使用TACEでも、比較的良好な局所制御の報告が多い。我々の施設においても、2012年より、肝細胞癌に対する血管内治療として、ミリプラチンを使用したマイクロバルーン閉塞下肝動脈化学塞栓療法（B-TACE）を主体に施行し、許容範囲内の局所制御、比較的軽微な有害事象を報告してきた。更なるB-TACEの局所制御能向上のため、最初はバルーン非閉塞下のC-TACEを行い、Lipiodolの停滞を認めた時点で、バルーン閉塞下のB-TACEを施行するC-TACEとB-TACEを組み合わせたCombined conve ntional and B-TACE（Combined-B-TACE）を2013年からは施行し有効症例を比較的多く経験する。Combined-B-TACEは、標的病変を含む治療域のバルーン閉塞による血行動態等の大きな影響を受けることなく、良好なLipiodol集積が得られ、従来のB-TACEのみを行うSimple-B-TACEよりも局所制御能が高い傾向にあることを報告してきた。ただし、5cm以上の肝細胞癌では、Combined-B-TACE施行直後十分なリピオドール沈着が確認されたにもかかわらず早期再発症例も散見され治療に難渋する症例を経験する。本発表では、自件例のみの限られた症例数ではあるが、Combined-B-TACEの中期治療成績を示し、当施設におけるミリプラチン使用Combined-B-TACEとマイクロスフィアによるdrug-eluting bead(DEB)-TACEの治療法選択や治療法変更に関する報告をさせていただく。

  • Radiation protection on patient and physician during Vascular Interventional Radiology for body disease Invited

    Masakazu Hirakawa

    The 78th Annual Meeting of the Japan Radiological Society  2019.4 

    　More details

    Event date： 2019.4

    Language：English   Presentation type：Symposium, workshop panel (public)  

    Venue：Yokohama   Country：Japan  

    As minimally invasive procedures in vascular Interventional Radiology (IR) are increasingly adopted and becoming more complex, many IR procedures can result in clinically significant radiation doses to patients and to the physicians and paramedical staff in room. The radiation protection of both patients and medical stuffs is of particular concern. Radiation-induced cataracts secondary to occupational exposure represent a recently recognized entity. In 2011, the International Commission on Radiological Protection (ICRP) recommended reduction the occupational exposure dose limit for the eye lens to 20 mSv/y. However, NRA (Nuclear Regulation Authority, Japan) does not respond to these newly introduced criteria. The NRA considers the action to respond to new criteria for lens of eyes applicable to occupational exposure as introduced in the IAEA safety standard. Recent study reported that occupational eye doses from IR procedures have the potential to exceed the new ICRP equivalent dose limit, particularly if no eye lens protective equipment is always used. Therefore, radiologists are supposed to play a pivotal role for the radiation dose reduction during IR procedures. In this symposium, I would like to emphasize the importance of patients’ dose reduction trial and reliable measurement of operators’ eye dose by using DOSIRIS [direct monitoring of eye lens dose in terms of Hp(3)]under lead glass during IR procedures through my clinical experience and previous studies.

  • 初回治療かつ5cm以上肝細胞癌に対するB-TACEとDEB-TACEの治療成績に関する検討

    平川雅和・菊池　嘉朋・井上昭宏・鶴田悟・酒井浩徳・三森功士

    第25回肝血流動態・機能イメージ研究会  2019.2 

    　More details

    Event date： 2019.2

    Language：Japanese  

    Venue：東京   Country：Japan  

    初回治療かつ5cm以上肝細胞癌に対するB-TACEとDEB-TACEの標的病変ごとの治療成績を報告する。対象は、ミリプラチン使用B-TACEで治療した18結節（平均腫瘍径5.9cm）とエピルビシン含浸DEB-TACEで治療した11結節（平均腫瘍径7.0cm）。初回治療後の局所治療効果および残存病変に対するB-TACEとDEB-TACEの局所治療効果をRECICLで評価した。結果：初回治療3ヵ月後Objective response rate（OR）は,B-TACE:DEB-TACEの38.9%: 54.5%。残存病変への治療後のORは、B-TACE後DEB-TACEで治療した標的病変vs DEB-TACE後B-TACEで治療した標的病変のOR：61.5% vs 81.8% であった。いずれの治療後も重篤な有害事象は認めなかった。結論：5cm以上肝細胞癌の局所制御能は、初回治療として、ミリプラチン使用B-TACEよりもDEB-TACEが良好な傾向であった。5cm以上肝細胞癌に対しては、DEB-TACEで腫瘍減量後、B-TACEでCRを目標とした治療戦略が局所制御能は良好な可能性がある。

  • Significant Importance of Novel Direct Eye Dosimeter and Protective Lead Devices for Complying with ICRP Recommended Limit for the Eye Lens in Transarterial Chemoembolization for HCC International conference

    @Masakazu Hirakawa, @Y Asayama, @K Ishigami, @Y Ushijima, @A Nishie, @H Honda

    Radiological Society of North America's 104th Scientific Assembly and Annual Meeting  2018.11 

    　More details

    Event date： 2018.11

    Language：English  

    Venue：Chicago   Country：United States  

    Objective This study aimed to evaluate the occupational eye doses estimated using novel direct eye dosimeter (DOSIRIS, 3mm dose equivalent, Hp(3)) during transarterial chemoembolization (TACE) for HCC and to investigate possible number of TACE procedures/y within current dose limit of 20 mSv/y.
    M&M The measurements of eye doses [Hp(3)]were carried out for 3 Interventional radiologists (IR) (IR1 operator with lead glass and ceiling mounted lead glass screen, IR2 operator without lead glass and with ceiling mounted lead glass screen, IR3 operator without lead glass and ceiling mounted lead glass screen) performing 132 TACE procedures using DOSIRIS. For protective lead devices, wraparound type lead glass eye wear (0.07mmPb) and ceiling mounted lead glass screen are used. To measure the occupational eye dose, DOSIRIS was stuck just lateral to the left eye under lead glass and without lead glass. We calculated the eye dose per TACE procedures and possible number of TACE procedures/ y within current dose limit of 20 mSv/y for each operators.
    Result The mean fluoroscopy time, air kerma and dose area product/TACE were 38.2min, 1.45Gy and 200587mGy・cm2, respectively. The eye dose per TACE procedure for 1,2, and 3 operator were 34.8, 72.2, and 240μSv, respectively. The eye dose of IR1 with protective lead devices was significantly lower than IR without protective lead devices (IR3). Possible number of TACE procedures /y within ICRP recommended dose limit of 20 mSv/y for 1, 2, and 3 operator were 574, 277, and 83, respectively.
    Conclusion The eye dose limit of 20mSv/y may be exceeded in IR operators who do not use protective lead glasses and ceiling mounted lead glass screen. For complying with ICRP recommendation, protective lead devices and correct evaluation of the eye dose using direct eye dosimeter (Hp(3)) under protective lead glasses might be needed.

  • 肝腫瘍に対するTACEと関連画像診断 Invited

    平川 雅和, @井上 昭宏, @鶴田 悟, @酒井 浩徳, 三森 功士 , 本田 浩

    第54回日本医学放射線学会秋季臨床大会  2018.10 

    　More details

    Event date： 2018.10

    Language：Japanese   Presentation type：Oral presentation (general)  

    Venue：福岡   Country：Japan  

    近年、肝炎ウィルスの治療成績の向上に伴い肝細胞癌患者は減少傾向であるが、依然として、放射線科医が関与するIVRにおいて、肝細胞癌に対するTACEは、比較的多くを占めている。TACEの治療成績向上かつマンパワーや時間的に効率的な治療を遂行していくためには、術前・術中の画像診断および積極的に新たなデバイスや薬剤、医療材料を使用していくことが、非常に重要と考えられる。
    B-TACEは、2012年頃より本邦において、入江先生らにより肝細胞癌に対して施行されており、近年、比較的良好な局所制御能を報告する文献が散見される。我々もB-TACE治療成績を報告しており、過去のTACEに関する報告と同程度の局所制御能で、許容範囲だが、全生存期間（OS）を延長できる可能性を報告している。
    また、2014年より本邦でも臨床使用可能となった球状塞栓物質使用したDEB-TACEの有効性、 有害事象、先行する海外報告の治療成績等との相違等が報告されている。我々の施設においても、両葉多発症例、5cm 以上の比較的大きな肝細胞癌、従来のリピオドールを使用した TACE 後の難治症例に対して、DEB-TACE施行している。大型肝細胞癌症例では、 従来の リピオドールを使用した TACE と比較して、塞栓後症候群を含んだ 有害事象は軽く、治療効果に関しても、経過観察画像において、十分な治療効果が確認可能で、大型肝細胞癌に対して、 DEB-TACEを施行することは、多くの先生方に賛同得られるものと考えられる。両葉多発症例では、DEB-TACEによりCRが得られる症例は、かなり限られているが、PR,SDを維持可能症例もある。
    HCCに対するTACEでは、5cm以下のHCCでは、初回は、B-TACEを、大きなHCCや両葉多発症例にはDEB-TACEを施行し、以後On demandのB-TACEの DEB-TACEを組み合わせることで、肝機能低下も許容範囲内で、長期生存が得られる症例もあり、本発表では、肝細胞癌に対するバルーン閉塞下TACE(B-TACE)や球状塞栓物質使用TACE(DEB-TACE)と関連する画像診断、支援ソフトを用いた役立つ術中画像等について、症例を中心に概説させていただきます。

  • Let’s start Balanced-TACE Invited

    平川 雅和, 井上 昭宏, 鶴田 悟, 酒井 浩徳, 三森 功士

    Next Generation IVR Meeting  2018.9 

    　More details

    Event date： 2018.9

    Language：Japanese   Presentation type：Oral presentation (general)  

    Venue：札幌   Country：Japan  

  • 肝細胞癌に対するB-TACEの現状と展望

    平川 雅和, 井上 昭宏, 鶴田 悟, 酒井 浩徳, 三森 功士

    第54回日本肝癌研究会  2018.6 

    　More details

    Event date： 2018.6

    Language：Japanese   Presentation type：Symposium, workshop panel (public)  

    Venue：久留米   Country：Japan  

    Current status and prospect of B-TACE for hepatocellular carcinoma

  • DEB-TACEのポジショニング　大型肝細胞癌 Invited

    平川 雅和, 井上 昭宏, 鶴田 悟, 酒井 浩徳, 三森 功士

    ディーシービーズ　シンポジウム  2018.6 

    　More details

    Event date： 2018.6

    Language：Japanese  

    Venue：Tokyo   Country：Japan  

  • Let’s start Balanced-TACE Invited International conference

    Masakazu Hirakawa, T Yamanouchi, A Inoue, S Tsuruta, H Sakai, K Mimori, H Honda

    JSIR, ISIR 2018  2018.5 

    　More details

    Event date： 2018.5 - 2018.6

    Language：English  

    Venue：Tokyo   Country：Japan  

  • Evaluation of the occupational eye doses estimated using direct eye dosimeter during TACE for HCC International conference

    Masakazu Hirakawa, Y Torahiko, S Tsuruta, A Inoue, H Sakai, K Mimori, H Honda

    JSIR, ISIR 2018  2018.5 

    　More details

    Event date： 2018.5 - 2018.6

    Language：English  

    Venue：Tokyo   Country：Japan  

    Objective This study aimed to evaluate the occupational eye doses estimated using novel direct eye dosimeter (DOSIRIS, 3-mm dose equivalent, Hp(3)) during transarterial chemoembolization (TACE) for HCC and to investigate possible number of TACE procedures y-1 within current dose limit of 20 mSv y-1. M&M The eye doses [Hp(3)] of 3 Interventional radiology(IR) operators (1 operator with lead glass and ceiling mounted lead glass screen, 2 operator without lead glass and with ceiling mounted lead glass screen, 3 operator without lead glass and ceiling mounted lead glass screen) were recorded using DOSIRIS. 96 TACE procedures were included in this study. For eye protective equipment, wraparound type lead glass eye wear (0.07mmPb) are used. To measure the occupational eye dose, DOSIRIS was stuck just lateral to the left eye under lead glass and without lead glass. We calculated the eye dose per TACE procedures and possible number of TACE procedures y-1 within current dose limit of 20 mSv y-1for each operators. Result The mean fluoroscopy time, air kerma and dose area product were 38.1 min, 1.62 Gy and 183.2 Gy cm2, respectively. The eye dose per TACE procedure for 1,2, and 3 operator were 35.9μSv, 76.2μSv, and 236.4μSv, respectively. Possible number of TACE procedures y-1 for 1, 2, and 3 operator were 557, 262, and 85, respectively. Conclusion The eye dose limit of 20mSv y-1 may be exceeded in IR operators who do not use protective lead glasses and ceiling mounted lead glass screen. Correct evaluation of the eye dose (Hp(3)) using direct eye dosimeter might be needed.

  • Comparison of occupational eye radiation dose estimated on novel direct eye dosimeter and film badge in transarterial chemoembolization for hepatocellular carcinoma

    Masakazu Hirakawa, Y Torahiko, H Wakiyama, K Matsumoto, K Sakamoto, S Tsuruta, A Inoue, H Sakai, K Mimori, H Honda

    第77回日本医学放射線学会総会  2018.4 

    　More details

    Event date： 2018.4

    Language：English  

    Venue：Yokohama   Country：Japan  

    Objective This study aimed to compare the occupational eye doses estimated using novel direct eye dosimeter (DOSIRIS) and film badge during transarterial chemoembolization (TACE) and to investigate possible number of TACE procedures y-1. M&M Thirty six HCC cases (17 men, 19 women; mean age, 76.4 years) treated with TACE over a 6-month period were included in this study. For eye protective equipment, wraparound type lead glass eye wear (0.07mmPb) are used. The personal film badge dosimeter (Hp(0.07)) stuck on the left side of the cap and DOSIRIS (Hp(3)) was stuck just lateral to the left eye under lead glass to measure the occupational eye dose. We calculated the cumulative 6-month eye dose and realistic eye dose per TACE procedures. RESULTS The mean fluoroscopy time, air kerma and dose area product were 40.9 min, 2.09 Gy and 129.8 Gy cm2, respectively. The cumulative 6-month eye dose and eye dose per procedure on DOSIRIS was 1.4 mSv and 38. 9μSv, respectively. Legal cumulative 6-month eye dose and eye dose per procedure estimated on film badge was 2.4 mSv and 66.7μSv, respectively. Possible number of TACE procedures y-1 within current dose limit of 20 mSv y-1 estimated on DOSIRIS and film badge was 514 and 300, respectively.CONCLUSION The new eye dose limit of 20mSv y-1 may be exceeded in interventional radiological physicians who do not wear protective lead glasses. Correct evaluation of the eye dose (Hp(3)) using novel direct eye dosimeter might be needed.

  • 肝細胞癌に対するエピルビシン含浸球状塞栓物質使用肝動脈化学塞栓療法（DEB-TACE）の治療成績

    平川雅和,山之内寅彦,井上昭宏,江口英利,黒田陽介,鶴田悟,酒井浩徳,三森功士

    第2回大分肝胆膵研究会  2018.3 

    　More details

    Event date： 2018.3

    Language：Japanese  

    Country：Japan  

    対象は、経皮的治療や切除不能肝細胞癌を有する36症例に対してエピルビシン含浸DC beads使用TACE（DEB-TACE）を58 sessions。局所制御、有害事象を後方視的に検討した。結果：患者背景、男性20例女性16例、平均年齢71.3歳で、腫瘍個数1/2/3/4個以上：12/11/2/11例、前治療歴B-TACE/ RFA/手術:19/6/3例、肝機能Child-Pugh A/B:20/16例。
    治療後2週間以内CTにて標的結節治療効果度TE1/TE2/TE3/TE4:2/9/35/12で、OR 81.0%であった。3ヵ月後の治療効果はmRECISTで、PD/SD/PR/CR:22/12/13/11で、OR41.4% であった。有害事象は、ほとんどはGrade１で、Grade2胆管炎、胆嚢炎2例、Grade3肝障害1例を認めた。
    結論　過去報告と比較し、本検討の局所制御能は低い傾向であった。

  • 肝細胞癌に対するマイクロバルーン閉塞下シスプラチン動注併用DEB-TACEに関する検討

    平川雅和,山之内寅彦,坂本勝美,脇山浩明,松本圭司,井上昭宏

    2018.2 

    　More details

    Event date： 2018.2

    Language：Japanese  

    Venue：福岡   Country：Japan  

    シスプラチン（CDDP）含浸球状塞栓物質（ヘパスフィア）使用TACE（DEB-TACE）の有効症例に関する報告が散見される。マイクロバルーン閉塞下CDDP動注併用DEB-TACEにて治療した肝細胞癌10症例14 sessionの治療成績を報告する。患者背景は、平均67歳,男/女=8/2．背景肝の内訳はHBV/HCV/NBNC＝2/7/1。全症例でTACEの前治療歴（B-TACE1-8回、DCbead1-3回）があり、CDDPの前治療歴なし。Child-Pugh分類はA/B/C＝6/3/1。BCLC分類ではIntermediate stage（B）/Advanced stage（C）＝8/2であった。治療法は、メーカー推奨のヘパスフィア調整法に沿ってアイエーコール100mg＋造影剤20ml＋10%NaCl5ml溶解液の15mlをマイクロバルーン閉塞下に治療域に動注した。引き続き溶解液10mlにて含浸したヘパスフィア50-100μmを初期はバルーン閉塞下、引き続きバルーン非閉塞下で動注した。3か月後CTをmRECISTにて評価した治療効果は、CR/PR/SD/PD＝1/5/3/5で、奏効率は42.9％であった。重篤な有害事象は認めなかった。TACE治療暦があり治療効果不十分と判断された症例においても本治療法が奏効する症例がある。

  • 最新の実臨床に基づいたディーシービーズのポジショニング Invited

    平川 雅和, 井上 昭宏, 鶴田 悟, 酒井 浩徳, 三森 功士

    2017.12 

    　More details

    Event date： 2017.12

    Language：Japanese  

    Venue：大分　中津   Country：Japan  

    最新の実臨床に基づいたディーシービーズのポジショニング

  • 肝細胞癌に対するミリプラチン使用バルーン閉塞下肝動脈化学塞栓療法（B-TACE）治療成績および予後予測因子に関する検討

    平川雅和,山之内寅彦,井上昭宏,鶴田悟3,酒井浩徳,三森功士

    第40回九州IVR研究会  2017.12 

    　More details

    Event date： 2017.12

    Language：Japanese  

    Venue：福岡   Country：Japan  

    肝細胞癌に対するミリプラチン使用バルーン閉塞下肝動脈化学塞栓療法（B-TACE）の治療成績と予後予測因子を報告する。対象はミリプラチン使用B-TACE施行した肝細胞癌症例42例。Overall survival (OS) およびProgression-free survival (PFS) および各予後予測因子を解析した。OS（中央値）は3.5年、PFS(中央値)は8ヶ月であった。OSに関与する予後予測因子は、ECOG performance status 0のみであった。PFSに関しては、単変量解析では、バルーン閉塞により腫瘍濃染増強, PVTTなし, 4 tumors of 7 cm criterion1以内, 初回 TACEが関与していたが、多変量解析では、有意な因子は確認できなかった。結論：ミリプラチン使用B-TACEは、局所制御能は従来報告されているc-TACEと同等ではあるが、OSは、良好な可能性がある。

  • Assessment of the occupational radiation dose to eye lens of interventional physicians during transarterial chemoembolization for hepatocellular carcinoma International conference

    Masakazu Hirakawa, Y Asayama, K Ishigami, Y Ushijima, A Nishie, H Honda

    103rd RSNA Scientific Assembly and Annual Meeting  2017.11 

    　More details

    Event date： 2017.11 - 2017.12

    Language：English  

    Venue：Chicago   Country：United States  

    PURPOSE
    This study aimed to estimate lens doses using film badge and electronic pocket dosimeter and to investigate correlations between occupational lens doses and patient doses during transarterial chemoembolization (TACE) for hepatocellular carcinoma.

    METHOD AND MATERIALS
    Fifty eight HCC cases (31 men, 27 women; mean age, 74.4 years, mean BMI, 25.5) treated with TACE (Lipiodol-TACE: 53, DEB-TACE: 5) were included in this study. The DSA machine was equipped with a 16-inch flat-panel detector. For eye lens protective equipment, the ceiling-mounted lead screen and wraparound type lead glass eyewear (0.07mmPb, calculation-based correction factor: 0.5) are used. The both film badge dosimeter (radiophotoluminescence glass dosimeter (RGDs), Hp(10 and 0.07)) and electronic pocket dosimeter(Silicon semiconductor detector, Hp(10)) were stuck on the left side of the cap to measure the maximum eye dose. Eye lens dose were estimated from measured radiation dose on both dosimeters. Additionally, dose area product (DAP), air kerma(AK) and fluoroscopy time of each TACE procedures were recorded from DSA machine.

    RESULTS
    The mean fluoroscopy time, AK and DAP were 38.1 min, 1.21Gy and 297.7 Gy cm2, respectively. The unprotected eye lens dose per procedure measured on film badge tended to be higher than that of pocket dosimeter (65.5μSv vs. 26.4μSv), respectively. The protected eye lens dose per procedure on film badge tended to be higher than that of pocket dosimeter (32.75μSv vs. 13.2μSv), respectively. Estimated eye dose per unit DAP on pocket dosimeter and film badge was 0.89μSvGy-1cm-2 and 2.21μSvGy-1cm-2, respectively.The current dose limit of 20 mSv /year can be reached for 305 and 610 TACE procedures /y for the operator without and with lead glass eyewear, respectively.

    CONCLUSION
    The current dose limit of 20 mSv /year can be reached for a few hundreds of TACE procedures /y without lead glass eyewear. Occupational eye doses from interventional radiology procedures have the potential to exceed the new ICRP equivalent dose limit, particularly if no eye lens protective equipment is always used.

  • B-TACE主体施設からのからのB-TACEとDEB-TACEの使い分け Invited

    平川雅和, 井上昭宏, 鶴田悟, 酒井浩徳, 三森 功士

    第53回日本肝癌研究会  2017.7 

    　More details

    Event date： 2017.7

    Language：Japanese   Presentation type：Symposium, workshop panel (public)  

    Venue：東京   Country：Japan  

    我々の施設においては、肝細胞癌に対する血管内治療として、マイクロバルーン閉塞下肝動脈化学塞栓療法（B-TACE）を主体に行っており、B-TACEは、肝細胞癌に対する局所制御能が、比較的良好な局所制御能を有することを報告してきた。ただし、有効症例のみならず早期再発症例も散見され、バルーンの位置や血行動態の変化の程度等の局所制御能に関する様々な交絡因子も最近報告されている。B-TACEの局所制御能向上のため、最初はバルーン非閉塞下のC-TACEを行い、Lipiodolの停滞を認めた点で、バルーン閉塞下のB-TACEを施行するC-TACEとB-TACEを組み合わせたcombined conventional and B-TACE（Combined-B-TACE）を施行し、従来のB-TACEのみを行うSimple-B-TACEよりも局所制
    御能が高い傾向にあることを報告してきた。Combined-B-TACE施行後の局所制御不良症例の経験から、5cm以上のHCCや両葉多発症例対しては、マイクロスフィアによるdrug-eluting bead（DEB）-TACEを施行している。今回は、自件例のみの限られた症例数ではあるが、Combined-B-TACEとDEB-TACEの使い分けと局所制御能の比較や各残存病変、再発病変への対処等に関する考察を報告させていただく。

  • B-TACE: 手技の標準化 Invited

    平川雅和, 井上昭宏, 鶴田悟, 酒井浩徳, 三森 功士, 本田 浩

    第22回肝動脈塞栓療法研究会  2017.5 

    　More details

    Event date： 2017.5

    Language：Japanese   Presentation type：Oral presentation (general)  

    Venue：岡山県医師会館   Country：Japan  

  • Analysis of estimated eye lens radiation dose in Transarterial chemoembolization for Hepatocellular carcinoma

    Masakazu Hirakawa, Katsumi Sakamoto, Kotaro Terashima, Satoru Tsuruta, 酒井浩徳, Koshi Mimori, Hiroshi Honda

    第46回日本IVR総会  2017.5 

    　More details

    Event date： 2017.5

    Language：Japanese  

    Venue：okayma   Country：Japan  

    OBJECTIVE: This study aimed to estimate lens doses using film badges and ele ctronic pocket dosimeters and to investigate correlations between occupation al lens doses and patient doses during TACE for hepatocellular carcinoma. M ATERIALS AND METHODS: Sixty HCC cases (37 men; mean age, 73.8 years) treated with TACE were included in this study. The DSA machine was equipped with a 16-inch flat-panel detector. The operators wear protective aprons and thyroi d collars. For eye lens protective equipment, wraparound type lead glass eye wear (0.07 mmPb, calculation-based correction factor: 0.5) were used. Both t he film badge dosimeter (Hp(0.07)) and electronic pocket dosimeter (Hp(10)) were stuck on the left side of the cap to measure the maximum eye dose. Eye lens doses were estimated from measured radiation doses on both dosimeters.
    Additionally, the dose area product (DAP), air kerma (AK), and fluoroscopy t ime of each TACE procedure were recorded from the DSA machine. RESULTS: The mean fluoroscopy time, AK, and DAP were 39.7 min, 1.28Gy, and 307.7Gy cm <SU
    P>2#UR, respectively. The measured doses on the pocket dosimeter and
    P>esti
    mated eye lens dose per procedure tended to be higher than that of the film badge (84.9 vs. 64.4 and 42.5 vs. 32.2 (&mu;Sv)), respectively. The estimate d eye dose per unit DAP on the pocket dosimeter and film badge were 0.28 and
    0.21 &mu;SvGy-1cm-2, respectively. CONCLUSION: The r esults show that the current dose limit of 20 mSv y -1 can be rea ched for 621 TACE procedures y -1 for the operator when the eye l ens protective equipment is always used.

  • Analysis of eye lens radiation dose estimated on film badge and electronic p ocket dosimeter in transarterial chemoembolization

    Masakazu Hirakawa, Kimitaka Miyajima, Kotaro Terashima, Katsumi Sakamoto, Satoru Tsuruta, 酒井浩徳, Koshi Mimori, Hiroshi Honda

    第76回日本医学放射線学会総会  2017.4 

    　More details

    Event date： 2017.4

    Language：Japanese  

    Venue：Yokohama   Country：Japan  

    Objective This study aimed to estimate lens doses using film badge and elect ronic pocket dosimeter and to investigate correlations between occupational lens doses and patient doses during transarterial chemoembolization (TACE) f or hepatocellular carcinoma. Materials and Methods Forty HCC cases (23 men,
    17 women; mean age, 72.8 years) treated with TACE were included in this stu dy. The DSA machine was equipped with a 16-inch flat-panel detector. The ope rators wear protective apron and thyroid collar. For eye lens protective equ ipment, wraparound type lead glass eyewear (0.07mmPb, calculation-based corr ection factor: 0.5) are used. The both film badge dosimeter(Hp(0.07)) and e lectronic pocket dosimeter(Hp(10)) were stuck on the left side of the cap to measure the maximum eye dose. Eye lens dose were estimated from measured ra diation dose on both dosimeters. Additionally, dose area product(DAP), air k
    erma(AK) and radiation time of each TACE procedures were recorded from DSA m achine.RESULTS The mean fluoroscopy time, AK and DAP were 36.9 min, 1.21Gy a nd 294.7 Gy cm2, respectively. Measured dose on pocket dosimeter and estimated eye lens dose per procedure tended to be higher than that of f ilm badge (111 vs. 67.5 and 55.5 vs. 33.75(&mu;Sv)), respectively. Estimated eye dose per unit DAP on pocket dosimeter and film badge were 0.42 and 0.23 &mu;SvGy-1cm-2, respectively. These estimated eye dose was comparable, compared to previous reports. CONCLUSION The results show that the current dose limit of 20 mSv y-1 can be reached for 360 TACE procedures y-1 for the first operator when the eye lens prot ective equipment is always used.

  • A Significant and simple trial of radiation dose reduction during transarterial chemoembolization (TACE) with drug-eluting bead (DEB) for hepatocellular carcinoma International conference

    Masakazu Hirakawa, Kotaro Terashima, Katsumi Sakamoto, Satoru Tsuruta, Hironori Sakai, Koshi Mimori, Hiroshi Honda

    2017 European congress Radiology  2017.3 

    　More details

    Event date： 2017.3

    Language：English  

    Venue：Vienna   Country：Australia  

    OBJECTIVE This study aimed to evaluate patient radiation dose reduction, during transarterial chemoembolization (TACE) with drug-eluting bead (DEB) for hepatocellular carcinoma (HCC) while maintaining treatment effect (TE), adverse events(AE) and the image quality (IQ), using a new our clinical trial of radiation dose reduction. MATERIALS AND METHODS Ninety HCC cases treated with DEB-TACE were included in this study. Forty five patients (30 men, 15 women; mean age, 71.6 years) were treated under normal mode(the normal group), and 45 patients (28 men, 17 women; mean age, 70.8 years) were treated under radiation reduction mode using reduction filter (0.4mmCu+1.0mmAl), half frame rate and reduction of detector dose rate (the reduction group). Dose area product (DAP), air kerma (AK) and radiation time of each digital fluoroscopy (DF) were compared between the two groups. IQ of digital subtraction angiography (DSA) and digital angiography (DA) during infusion of DEB was assessed by two blinded and independent readers on a four-rank scale. RESULTS There were no significant differences in patient's characteristics and tumor burden between the groups. The overall adverse events relating DEB-TACE did not significantly differ between the groups. Fluoroscopy time were equivalent between the groups. Compared to the normal group, in the reduction group, AK and DAP could be significantly reduced by 65.4% (2.63 Gy vs. 1.72 Gy, p<0.05) and 69.2% (48300 mGy cm2 vs. 33400 mGy cm2, p<0.05), respectively. TE, AEs and IQ were rated comparable between the groups. CONCLUSION: Our simple trial of radiation dose reduction during DEB-TACE for HCC could reduce to almost 65% level recorded in the normal mode without negative impact on treatment effect, image quality and severe adverse events. IR doctors should review default setting of own angiography system and DEB-TACE procedure.

  • 肝細胞癌に対するCombined conventional and B-TACEにおける薬剤押し込み効果に関する検討

    平川雅和, 宮嶋公貴, 鶴田悟, 酒井浩徳, 三森 功士

    第23回 肝血流動態・機能イメージ研究会  2017.2 

    　More details

    Event date： 2017.2

    Language：Japanese  

    Venue：大阪   Country：Japan  

    我々は、肝細胞癌に対するC-TACEとマイクロバルーン閉塞下肝動脈化学塞栓療法（B-TACE）を組み合わせたcombined conventional and B-TACE（Combined-B-TACE）が、従来のB-TACEのみを行うよりも、バルーン閉塞前後の血行動態の変化にかかわらず、局所制御能が高い傾向にあることを報告してきた。これは、従来示されているB-TACEの引き込み効果よりB-TACEの押し込み効果が高い局所制御の重要な要因である可能性があると考えられる。今回、Combined-B-TACE において、B－TACEの押し込み効果の有効性を再検討した。対象は、過去Combined-B-TACEを施行した症例のうち、C－TACEおよびB－TACE直後のCTが撮影された40症例（男性２０例，平均年齢７４歳）。治療法は、C-TACEを行い、栄養血管内でリピオドールの停滞を認めた時点で、単純CTを撮影後、B-TACEを施行し単純CTを撮影する。評価方法は、各TACE直後のCTにおいて、標的結節のリピオドールの沈着程度を、４段階評価した。Grade1:標的結節の50％以下の沈着,Grade2:1と3の間,Grade3：75％-100％,Grade4：標的結節全体および周囲肝実質へのdenseな沈着や周囲門脈への沈着。3ヵ月後の局所制御能, CTCAEVer3.0を用いた有害事象(AEs) も評価した。結果：Grade3以上のAE は、Grade3の胆嚢炎を1例で認めた。各TACE直後のCTでの薬剤沈着程度C－TACE：G1/2/3/4：7/14/17/2, B－TACE：G1/2/3/4：0/0/9/31。3ヵ月後の局所制御能は82. 5%であった.結論Combined-B-TACEは、B－TACEの高い押し込み効果により比較的高い制御能を有していると考えられる。

  • A clinical trial of radiation dose reduction during transarterial chemoembolization(TACE) with drug-eluting bead(DEB) for hepatocellular carcinoma International conference

    Masakazu Hirakawa, Kousei Ishigami, Yasuhiro Ushijima, Akihiro Nishie, Hiroshi Honda

    The 102nd Scientific Assembly & Annual Meeting Radiological Society of North America  2016.12 

    　More details

    Event date： 2016.11 - 2016.12

    Language：English  

    Venue：Chicago   Country：United States  

    OBJECTIVE This study aimed to evaluate patient radiation dose reduction, during transarterial chemoembolization (TACE) with drug-eluting bead (DEB) for hepatocellular carcinoma (HCC) while maintaining treatment effect (TE), adverse events(AE) and the image quality (IQ), using a new our clinical trial of radiation dose reduction. MATERIALS AND METHODS Eighty five HCC cases treated with DEB-TACE were included in this study. Forty five patients (30 men, 15 women; mean age, 71.6 years) were treated under normal mode(the normal group), and 40 patients (25 men, 15 women; mean age, 69.6 years) were treated under radiation reduction mode using reduction filter, lower frame rate and etc (the reduction group). Dose area product (DAP), air kerma (AK) and radiation time of each digital fluoroscopy (DF) were compared between the two groups. IQ of digital subtraction angiography (DSA) and digital angiography (DA) during infusion of DEB was assessed by two blinded and independent readers on a four-rank scale. RESULTS There were no significant differences in patient's characteristics and tumor burden between the groups. The overall adverse events relating DEB-TACE did not significantly differ between the groups. Fluoroscopy time were equivalent between the groups. Compared to the normal group, in the reduction group, AK and DAP could be significantly reduced by 64.2% (2.63 Gy vs. 1.64 Gy, p<0.05) and 67.4% (483 Gy cm2 vs. 328 Gy cm2, p<0.05), respectively. TE, AEs and IQ were rated comparable between the groups. CONCLUSION In our clinical trial of radiation dose reduction, radiation dose could be reduced significantly without negative impact on treatment effect, image quality and severe adverse events.

  • 肝細胞癌に対するTACE　-B-TACE主体施設からの考察- Invited

    平川雅和, 宮嶋公貴, 鶴田悟, 酒井浩徳, 杉町 圭史, 三森 功士, 浅山 良樹, 本田 浩

    第52回　日本肝癌研究会  2016.7 

    　More details

    Event date： 2016.7

    Language：Japanese   Presentation type：Symposium, workshop panel (public)  

    Venue：東京   Country：Japan  

    我々の施設においては、2012年末より肝細胞癌に対する血管内治療として、マイクロバルーン閉塞下肝動脈化学塞栓療法（B-TACE）を主体に行っており、B-TACEは、肝細胞癌に対する局所制御能が、過去に施行したConventional-TACE（C-TACE）よりも良好な局所制御能を有することを報告してきた。ただし、B-TACE施行例のうち、有効症例のみならず早期再発症例もしばしば経験し、C-TACEの方が有効な症例あること、バルーンの位置や血行動態の変化の程度等の局所制御能に関する様々な交絡因子も最近

  • 肝細胞癌に対する最近のTACE　主にB-TACEについて（DEB-TAE) Invited

    平川雅和, 宮嶋公孝, 江口 英利, 鶴田悟, 酒井浩徳, 三森 功士

    2016.5 

    　More details

    Event date： 2016.5

    Language：Japanese   Presentation type：Symposium, workshop panel (public)  

    Country：Japan  

    肝細胞癌に対する最近のTACEとして、マイクロバルーン閉塞下肝動脈化学塞栓療法
    (Microballoon-occluded TACE：B-TACE)と薬剤溶出性球状塞栓物質による肝動脈化学塞栓療法(DEB-TACE)が、施行されるようになっている。
    従来のTACEでは、マイクロカテーテルを可能な限り腫瘍の近くまで、誘導し抗癌剤を注入する治療が主流であったが、近年、先端にバルーンを有するマイクロバルーンカテーテルを使用したB-TACEが広まりつつある。B-TACEでは、肝動脈内にてバルーン拡張し、肝動脈を

  • A clinical trial of radiation dose reduction during transarterial chemoembolization(TACE) with drug-eluting bead(DEB) for hepatocellular carcinoma

    Masakazu Hirakawa, Norio wada, Kotaro Terashima, Katsumi Sakamoto, Kimitaka Miyajima, Satoru Tsuruta, H Sakai, Koshi Mimori, Hiroshi Honda

    第45回　日本IVR学会  2016.5 

    　More details

    Event date： 2016.5

    Language：Japanese  

    Venue：名古屋   Country：Japan  

    OBJECTIVE This study aimed to evaluate patient radiation dose reduction, treatment effect (TE) and the image quality (IQ) during transarterial chemoembolization (TACE) with drug-eluting bead (DEB) for hepatocellular carcinoma (HCC). MATERIALS AND METHODS

  • IVRにおける放射線防護と被曝低減 Invited

    平川雅和, 本田 浩

    第75回日本医学放射線学会総会  2016.4 

    　More details

    Event date： 2016.4

    Language：Japanese   Presentation type：Oral presentation (general)  

    Venue：横浜   Country：Japan  

    近年、X線透視下で治療を行うInterventional Radiology (IVR)は、必要性が増加しているが、患者様、術者、介助者の被曝は問題となる。過去には、拡大透視や高線量率透視の長時間使用、撮影回数増加により、しきい線量を超えて、皮膚障害等の有害事象の報告もある。被曝低減の為には、時間・距離・遮蔽を基本とした術者等への教育並びに、パルス透視・付加フィルター・オートコリメーション等の装置側の改良が必要である。近年、肝細胞癌に対して、薬剤溶出性球状塞栓物質使用TACE（DEB-TACE）が施行され

  • A clinical trial of radiation dose reduction during transarterial chemoembolization(TACE) with drug-eluting bead(DEB) for hepatocellular carcinoma

    Masakazu Hirakawa, Noriaki Wada, Hidenari Hirata, Kotaro Terashima, Katsumi Sakamoto, Kimitaka Miyajima, Satoru Tsuruta, Hironori Sakai, Koshi Mimori, Hiroshi Honda

    第75回日本医学放射線学会総会  2016.4 

    　More details

    Event date： 2016.4

    Language：English  

    Venue：Yokohama   Country：Japan  

  • 肝細胞癌に対するCombined conventional and B-TACEの局所制御能：Simple B-TACEとの比較検討

    平川雅和, 和田憲明, 宮嶋公貴, 鶴田悟, 酒井浩徳, 杉町 圭史, 三森 功士, Hiroshi Honda

    動注化学療法フォーラム2016  2016.3 

    　More details

    Event date： 2016.3

    Language：Japanese  

    Country：Japan  

    肝細胞癌に対するCombined conventional and B-TACE（C-B-TACE)の局所制御能に関して、従来一般的に施行されているSimple B-TACEとの比較検討を行った。C-B-TACE30例とSimple-B-TAE45例での局所制御能は、優位さは認められないもののC-B-TACEで高い傾向であった。良好な局所制御が得られる予想されるメカニズムについて、肝の解剖学的および血行動態から考察する

  • 肝細胞癌に対するSimple B-TACEとCombined conventional and B-TACEの局所制御能の比較検討

    平川雅和, 和田憲明, 宮嶋公貴, 鶴田悟, 酒井浩徳, 杉町 圭史, Yoshiki Asayama, 三森 功士, Hiroshi Honda

    第22回 肝血流動態・機能イメージ研究会  2016.2 

    　More details

    Event date： 2016.2

    Language：Japanese  

    Venue：東京   Country：Japan  

    マイクロバルーン閉塞下肝動脈化学塞栓療法（B-TACE）は、肝細胞癌に対する局所制御能がConventional-TACE（C-TACE）よりも良好な局所制御能を有することを報告してきた。ただし、昨年の本研究会で、B-TACEが有効症例やC-TACEの方が有効な症例あること、バルーンの位置や血行動態の変化の程度等の局所制御能に関する様々な交絡因子が示された。我々は、C-TACEとB-TACEを組み合わせたcombined conventional and B-TACE（Combined-B-TACE）を施行しており、従来のB-TACEのみを行うSimple-B-TACEよりも局所制御能が高い傾向にあることを報告してきた。治療法は、まずC-TACEを行い、Lipiodolの停滞を認めた時点で、バルーン閉塞下のB-TACEを施行する。今回は、更にC-B-TACEの症例数を積み重ねたので、その局所制御能をS-B-TACEと比較検討した。対象は、初回TACEの69症例で、C-B-TACE group 24 症例とS-B-TACE group 45 症例。 方法は、TACE後の局所制御能は、Kaplan-Meier 法により, 有害事象は (AEs) は、CTCAEVer3.0を用いて評価した。結果：overall AEs は、各グループ間に有意差は認めなかった。 1週間後のobjective response rateと3ヵ月後の局所制御能は各グループ C-B-TACE group (92.3% and 85%) とS-B-TACE group (90.9% and 88.6%)で、ほぼ同等であった.6ヵ月後の局所制御能は、 C-B-TACE group (80%) がS-B-TACE group (73.3%) より高い傾向であった。結論Combined-B-TACE はSimple-B-TACEよりも高い制御能を有している可能性がある。

  • 薬剤溶出性球状塞栓物質使用TACE（DEB-TACE)後肝細胞癌に対して肝切除施行した1症例

    平川雅和, 宮嶋公貴, 鶴田悟, 酒井浩徳, 東保 太郎, 三森 功士

    2016.2 

    　More details

    Event date： 2016.2

    Language：Japanese  

    Venue：大分   Country：Japan  

    肝細胞癌に対する薬剤溶出性球状塞栓物質使用TACE（DEB-TACE)をこれまで、70例ほど施行してきた。従来のLipiodolを使用したLipiodol-TACEとDEB-TACEとの治療法選択に関しては、国内外で様々な報告がある。今回、DEB-TACE後肝細胞癌に対して肝切除施行した1症例を経験し、術後の病理学的検討において、興味深い所見を呈していた。この所見より、DEB-TACEとLipiodol-TACEをの使い分けに関する考察を報告する。

  • 肝細胞癌に対する球状塞栓物質使用肝動脈化学塞栓療法（DEB-TACE）時の被爆低減に関する初期臨床経験

    平川雅和, 和田　憲明, 宮嶋公貴, 鶴田悟, 酒井浩徳, 三森 功士

    第38回九州IVR研究会  2015.12 

    　More details

    Event date： 2015.12

    Language：Japanese  

    Venue：福岡   Country：Japan  

    球状塞栓物質使用肝動脈化学塞栓療法（DEB-TACE）時に、Lipiodol-TACEよりも、薬剤動態が確認困難、頻回の治療効果確認造影等にて、被爆増加が懸念される。DEB-TACE時の被爆低減に関する初期臨床経験を報告する。方法：球状塞栓物質（DCbeads）は、メーカ推奨調整法で、血管造影装置は、Allura Xper FD20/20(Phillips)を使用。薬剤注入時は、室内を暗くし、拡大透視や撮影を制限する。血管造影装置は、透視、撮影時のFrame rateと線量低減、被爆低減フィルターの使用の被爆低減モードにて治療した。結果：被爆低減措置なしの40症例と被爆低減措置ありの8例において、被爆低減措置により術中術後の有害事象の増加はなかった。従来モードよりも被爆低減モードでは、被爆量が75-80%となった。今回の被爆低減措置で、有害事象の増加なく、被爆低減の可能性が示唆された。

  • 肝細胞癌に対するマイクロバルーン閉塞下肝動注化学療法(B-TACE) Invited

    平川雅和, 宮嶋公孝, 鶴田悟, 酒井浩徳, 三森 功士

    ミリプラエリアフォーラム　In　沖縄  2015.11 

    　More details

    Event date： 2015.11

    Language：Japanese   Presentation type：Oral presentation (invited, special)  

    Venue：沖縄県医師会   Country：Japan  

  • 薬剤溶出性球状塞栓物質使用TACE（DEB-TACE)後肝細胞癌に対して肝切除施行した1症例

    平川雅和, 東保 太郎, 三森 功士

    ディーシービーズ適正使用症例検討会  2015.10 

    　More details

    Event date： 2015.10

    Language：Japanese  

    Venue：福岡   Country：Japan  

    症例は、NASHの67歳男性。肝機能はChild A。肝細胞癌に対する肝切除、ミリプラチン使用B-TACE,RFA施行歴あり。今回、S4に1cm弱のhigh-lowの再発HCC、S5に1.5cm、S6に2cm弱の動脈相で淡いhigh-lowの再発HCCを認めた。腫瘍マーカー正常。S4の再発HCCに対して、エピルビシン含浸DC bead 100-300 を使用したDEB-TACEを施行した。治療後造影で、栄養動脈の5心拍停滞をendpointとした。S5,6再発HCCに対しては、ミリプラチン使用B-TACEを施行した。治療後の有害事象なし。治療1週間後の造影CTでは、S4の結節は辺縁に淡い増強効果は認められるものの,ほぼ低吸収化しており、TE4と判定。S5,6のものには、淡いLipiodol沈着を認めるものの沈着不良部位あり。増強部位ははっきりしないがTE3と判定。S5,6再発HCCについては、Vascularity低く、今後のTACEでの治療が困難となる可能性があり、患者様との話し合いで、S4,S5,6の肝部分切除を施行した。手術標本病理検査にてS4のHCC辺縁に中分化HCCの残存認めたのに対して、S5,6のHCCには、明らかな残存Viable componentを認めなかった。

  • 当院における肝細胞癌に対するエピルビシン含有drug-eluting beads使用TACEの治療成績

    平川雅和, 和田憲明, 宮嶋公貴, 鶴田悟, 酒井浩徳, 三森 功士

    第20回大分最小侵襲治療法研究会  2015.10 

    　More details

    Event date： 2015.10

    Language：Japanese  

    Venue：大分   Country：Japan  

    対象は、経皮的治療や切除不能肝細胞癌を有する30症例に対してDC beads使用TACE（DEB-TACE）を37回施行した。局所制御、有害事象を後視法的に検討した。DEB-TACEは、区域レベルあるいは亜区域までマイクロカテーテルを挿入し、エピルビシンを可能な限りメーカー推奨の方法で含浸、調整したDC beadsを使用した。治療のエンドポイントは、肝機能を考慮しつつ、治療動脈の造影で、5心拍の造影剤停滞が得られることに設定した。結果：患者背景、男性22例女性8例、平均年齢72.4歳で、肝細胞癌腫瘍個数1個　12例,2個5例,3個2例4個以上11例、前治療歴B-TACE21例,RFA6例,手術3例、肝機能Child-Pugh A11例,B17例,C2例,背景肝HBV6例,HCV12例,アルコールおよびNASH　12例。
    使用DC beadsは、100-300: 22回, 300-500: 13回, 500-700: 2回。最終確認造影で、治療後2週間以内CTにて標的結節治療効果度TE1/TE2/TE3/TE4:7/9/9/12で、Objective response rate56.8%であった。有害事象は、ほとんどはGrade１で、Grade2胆管炎、胆嚢炎2例、Grade3肝障害1例を認めた。
    結論　過去の報告と比較して、本検討の局所制御能は低い傾向であった。DEB-TACEは、従来Lipiodol-TACEにおいて制御困難な症例で、高い治療効果が得られる可能性があるが、慎重な注入が必要な印象である。

  • 肝細胞癌に対する最新血管内治療 Invited

    平川雅和, 和田憲明, 宮嶋公貴, 鶴田悟, 酒井浩徳, 三森 功士

    別府市医師会メディカルセミナー  2015.10 

    　More details

    Event date： 2015.10

    Language：Japanese   Presentation type：Oral presentation (general)  

    Venue：別府市   Country：Japan  

  • Beyond “Simple” B-TACE: Combined Conventional and B-TACE Can Be Superior to Simple B-TACE? Invited International conference

    Masakazu Hirakawa, Keishi Sugimachi, Koshi Mimori, Hiroshi Honda

    JSIR, ISIR & APCIO 2015  2015.5 

    　More details

    Event date： 2015.5

    Language：English   Presentation type：Public lecture, seminar, tutorial, course, or other speech  

    Venue：Miyazaki   Country：Japan  

  • Microballoon-occluded transarterial chemoembolization (B-TACE) using Miriplatin for HCCCan B-TACE enhance the local control ? Invited International conference

    Masakazu Hirakawa, Keishi Sugimachi, Koshi Mimori, Hiroshi Honda

    JSIR, ISIR & APCIO 2015  2015.5 

    　More details

    Event date： 2015.5

    Language：English   Presentation type：Public lecture, seminar, tutorial, course, or other speech  

    Venue：Miyazaki   Country：Japan  

  • 肝細胞癌に対する血管内治療最前線 Invited

    平川雅和, 江口 英利, 鶴田悟, 酒井浩徳, 三森 功士

    別府胃腸会  2015.5 

    　More details

    Event date： 2015.5

    Language：Japanese   Presentation type：Oral presentation (general)  

    Venue：別府   Country：Japan  

    肝細胞癌に対する血管内治療として、マイクロバルーン閉塞下肝動脈科学塞栓療法（B-TACE)と薬剤溶出性球状塞栓物質によるTACEの治療法の紹介、治療成績、将来展望について紹介する。

  • Local control effect of Combined conventional and microballoon-occluded transarterial chemoembolization with miriplatin for hepatocellular carcinoma : a retrospective comparison of B- TACE with miriplatin

    Masakazu Hirakawa, Kimitaka Miyajima, Keishi Sugimachi, Satoru Tsuruta, Hironori Sakai, Koshi Mimori, Hiroshi Honda

    The 74th Annual Meeting of the Japan Radiological Society  2015.4 

    　More details

    Event date： 2015.4

    Language：Japanese  

    Venue：Yokohama   Country：Japan  

    OBJECTIVE This study aimed to compare the local control effects of microbal loon-occluded transarterial chemoembolization (B-TACE) and those of Combined conventional and B-TACE (C-B-TACE) with miriplatin (MPT) for hepatocellular carcinoma (HCC). MATERIALS AND METHODS Sixty HCC cases treated with first T ACE using MPT were included in this study. Sixteen patients (11 men, 5 women ; mean age, 66.3 years) were treated using C-B-TACE with MPT (the C-B-TACE g roup), and 44 patients (28 men, 16 women; mean age, 74.2 years) were treated using B-TACE with MPT (the B-TACE group). The local control rates (modified Response Evaluation Criteria in Solid Tumors [mRECIST]), time to local recu rrences (Kaplan-Meier and log-rank tests), and adverse events (AEs) were eva luated. RESULTS There were no significant differences in patient's character istics between the groups. The overall AE incidence did not significantly di ffer between the groups. According to the mRECIST, the objective response ra te including complete and partial responses one week after treatment and loc al control rate 3 months after treatment did not significantly differ betwee n the groups C-B-TACE group (92.3% and 84.6%, respectively) and the B-TACE g roup (90.9% and 88.6%, respectively). Overall, local recurrences 6 months af ter treatment in the C-B-TACE group tended to be lower than in the B-TACE gr oup without statistical significance. CONCLUSION C-B-TACE tended to be assoc iated with lower local recurrence rate than B-TACE, and both showed similar adverse effects.
    OBJECTIVE
    This study aimed to compare the local control effects of microballoon-occluded transarterial chemoembolization (B-TACE) and those of Combined conventional and B-TACE (C-B-TACE) with miriplatin (MPT) for hepatocellular carcinoma (HCC).
    MATERIALS AND METHODS
    Sixty HCC cases treated with first TACE using MPT were included in this study. Sixteen patients (11 men, 5 women; mean age, 66.3 years) were treated using C-B-TACE with MPT (the C-B-TACE group), and 44 patients (28 men, 16 women; mean age, 74.2 years) were treated using B-TACE with MPT (the B-TACE group). The local control rates (modified Response Evaluation Criteria in Solid Tumors [mRECIST]), time to treatment failures (Kaplan-Meier and log-rank tests), and adverse events (AEs) were evaluated.
    RESULTS
    There were no significant differences in patient’s characteristics between the groups. The overall AE incidence did not significantly differ between the groups. According to the mRECIST, the objective response rate including complete and partial responses one week after treatment did not significantly differ between the groups C-B-TACE group (92.3%) the B-TACE group (90.9%). Overall, local recurrences in the C-B-TACE group tended to be lower than in the B-TACE group without statistical significance. Local control rate 3 months after treatment C-B-TACE group (84.6%) the B-TACE group (88.6%)
    CONCLUSION
    C-B-TACE tended to be associated with a higher objective response rate and lower local recurrence rate than B-TACE, and both showed similar adverse effects.

  • バルーン非閉塞・閉塞下CTAで血流変化を確認し、B-TACEにより、良好な治療効果を認めた低血流の肝細胞癌の１例

    平川雅和, 染原涼, 宮嶋公貴, 鶴田悟, 酒井浩徳

    2015.2 

    　More details

    Event date： 2015.2

    Language：Japanese  

    Venue：東京   Country：Japan  

    低血流の肝細胞癌への通常TACEでは、薬剤集積に難渋する症例を経験するが、マイクロバルーン閉塞下TACE(B-TACE)でも、良好なリピオドール（LPD）沈着が得られる症例も、決して多くはない。今回、バルーン閉塞による血行動態変化をCTAで確認し、低血流肝細胞癌ながらB-TACEによる良好なLPD沈着が得られた症例を経験したので、B-TACE中の動画を含めて報告させていただくと共に、低血流肝細胞癌に対するTACE治療効果向上への突破口としたい。
    症例は、80歳台女性。C型慢性肝炎にて経過観察中、肝S4/8ドーム下に2㎝弱の血流豊富な部分と低血流部分を有する肝細胞癌を認めた。ミリプラチン（MPT）+LPD懸濁液使用したB-TACEを施行し、良好なLPD集積を認めた。10か月後のCTで、LPDのwashoutを認めたが、造影CTおよびGd-EOB-DTPA造影MRIでも血流を確認できなかった。拡散強調画像にて病変部は高信号を呈し、腫瘍マーカーの上昇を認めた。血管造影では、前回治療したA8は、開存しており、バルーン非閉塞下での血管造影およびCTAで、明らかな腫瘍濃染は指摘できなかったが、バルーン閉塞下でのCTAで、AP shunt の顕在化を認め、腫瘍部分に淡い増強効果を認めた。バルーン非閉塞状態でのMPT+LPD懸濁液の注入では、腫瘍への明らかなリピオドールの沈着は指摘できなかったが、B-TACEでは、非閉塞下で認められなかった栄養動脈および腫瘍への良好なLPDの沈着を認めた。治療後のCTでも、良好なLPD沈着が確認された。

  • 肝細胞癌に対するミリプラチン使用Combined conventional and B-TACEの治療成績の検討

    平川雅和, 染原涼, 宮島公貴, 杉町 圭史, 鶴田悟, 酒井浩徳, 三森 功士

    九州IVR研究会  2014.12 

    　More details

    Event date： 2014.12

    Language：Japanese  

    Venue：福岡   Country：Japan  

    HCCに対するミリプラチン使用マイクロバルーン閉塞下TACE（B-TACE）の比較的良好な局所制御を報告してきた。ただし、バルーン非閉塞下より閉塞下造影で、栄養動脈やstainが、描出不良となる症例を経験する。このため、バルーン非閉塞下のConventional-TACEの方が、B-TACEよりも局所制御良好な症例の存在も予測される。バルーン非閉塞下に引き続き閉塞下でTACE（Combined conventional and B-TACE: C-B-TACE）を12例に施行した。従来のB-TACE（44例）との局所制御、有害事象を後視法的に比較検討した。重篤な有害事象はなく、3か月局所制御率C-B-TACE/B-TACEは、83.3%/88.6%であった。3か月以降の局所制御はC-B-TACEが良好な印象であり、C-B-TACEは、B-TACEよりも良好な局所制御が得られる可能性がある。

  • 多血性肝腫瘍に対するエピルビシン含有drug-eluting beads使用TACEの初期治療成績

    平川雅和, 染原涼, 宮島公貴, 杉町 圭史, 鶴田悟, 酒井浩徳, 三森 功士

    九州IVR研究会  2014.12 

    　More details

    Event date： 2014.12

    Language：Japanese  

    Venue：福岡   Country：Japan  

    Initial Result of TACE with Epirubicin loaded drug-eluting beads for hypervascular liver tumor

  • Significant efficacy of new microballoon-occluded transarterial chemoembolization with miriplatin for hepatocellular carcinoma : a retrospective comparison of conventional TACE with epirubicin International conference

    Masakazu Hirakawa, Kimitaka Miyajima, Keishi Sugimachi, Satoru Tsuruta, hironori Sakai, Koshi Mimori, Hiroshi Honda

    100th annual meeting Radiological Society of North America  2014.11 

    　More details

    Event date： 2014.11 - 2014.12

    Language：English  

    Venue：Chicago, IL   Country：United States  

    Objective: This study aimed to compare the local control effects of microballoon-occluded transarterial chemoembolization (B-TACE) with miriplatin (MPT) and those of TACE with epirubicin (EPIR) for hepatocellular carcinoma (HCC).

    MATERIALS AND METHODS: Sixty-five HCC cases were treated with TACE using EPIR or MPT. Forty patients (25 men, 15 women; mean age, 73.4 years) were treated using B-TACE with MPT (the MPT-B-TACE group), and 25 patients (15 men, 10 women; mean age, 72.2 years) were treated using TACE with EPIR (the EPIR-TACE group). The local control rates (modified Response Evaluation Criteria in Solid Tumors [mRECIST]), time to local recurrence (Kaplan-Meier and log-rank tests), and adverse events (AEs) were evaluated. Statistical analyses were conducted to evaluate the relationship between the patient’s characteristics and local recurrence after MPT-B-TACE using Pearson's Chi-squared test. Multivariate logistic regression analysis was also performed.

    RESULTS: There were no significant differences in patient’s characteristics between the groups. The overall AE incidence did not significantly differ between the groups. According to the mRECIST, the objective response rate including complete and partial responses, in the MPT-B-TACE group (92%) was significantly higher than that in the EPIR-TACE group (76%). Overall, local recurrences in the MPT-B-TACE group were significantly lower than in the EPIR-TACE group (p < 0.05). Excluding multiple HCC cases, the local recurrence rate in the MP T-B-TACE group was significantly lower than in the EPIR-TACE group (p < 0.05).
    Local recurrence after MPT-B-TACE was recognized in the 35% patients in the follow-up periods. Tumor size larger than 2cm and tumor number more than three HCCs were significant key factors in the local recurrence after MPT-B-TACE.
    CONCLUSION
    MPT-B-TACE was associated with a higher objective response rate and lower local recurrence rate than EPIR-TACE, and both showed similar adverse effects. Tumor size larger than 2cm and tumor number more than three HCCs were risk factors of the local recurrence after MPT-B-TACE.

  • 乳腺疾患に対するトモシンセシス機能搭載マンモグラフィの初期使用経験

    平川雅和, 新田 吉陽, 三森 功士

    大分総合画像診断研究会  2014.10 

    　More details

    Event date： 2014.10

    Language：Japanese  

    Venue：大分   Country：Japan  

    当院は、乳腺疾患の患者様の比率が高い施設で、従来よりも詳細な乳腺の評価が可能なマンモグラフィ検査を目的として、乳房断層像を生成するトモシンセシスを搭載したマンモグラフィ富士フイルムメディカル株式会社製「AMULET Innovality」を、本年3月より導入した。
    当院では、CC画像は２D画像のみで、トモシンセシス画像を、MLOの２D通常画像に追加している。読影に関しては、５Mモニターの専用読影端末を導入し、乳腺外科医、放射線科医のダブルチェックを行っている。導入後7か月で、113症例の乳腺疾患の患者様に、本装置でのマンモグラフィ検査を施行した。デンスブレストにより、乳腺との重なりで、２D画像では、検出困難な病変が、トモシンセシス画像で、容易に異常所見として検出可能となった有用症例を経験している。トモシンセシス画像追加のメリットや本装置の有用性等につき報告する。

  • 多血性肝腫瘍に対するエピルビシン含有drug-eluting beads使用TACEの初期治療経験

    平川雅和, 染原涼, 宮嶋公貴, 鶴田悟, 杉町 圭史, 酒井浩徳, 三森 功士

    第19回　大分最少侵襲治療研究会  2014.10 

    　More details

    Event date： 2014.10

    Language：Japanese  

    Venue：大分   Country：Japan  

    経皮的治療困難や切除不能多血性肝腫瘍を有する14症例( 男性10例, 女性4例、平均年齢71.8歳、肝細胞癌13例、NET肝転移1例)に対してdrug-eluting beads使用TACE（DEB-TACE）を16回施行した。DEB-TACEは、区域レベルあるいは亜区域までマイクロカテーテルを挿入し、エピルビシンを可能な限りメーカー推奨の方法で含浸、調整したDC beadsを使用した。使用DC beadsは、100-300: 9回, 300-500: 6回, 500-700: 1回。治療後CTにて標的結節治療効果度TE1/TE2/TE3/TE4: 6/3/4/3であった。CTCAE Ver3.0での有害事象は、Grade2以下の塞栓後症候群が主であったが、1例でGrade3の肝酵素の一過性上昇を認めた。DEB-TACEは、症例を選択することで、高い治療効果が得られる可能性があるが、慎重な注入が必要な印象である。

  • 肝細胞癌に対するミリプラチン使用マイクロバルーン閉塞下TACEの中期治療成績の検討

    平川雅和, 染原涼, 宮嶋公貴, 鶴田悟, 杉町 圭史, 酒井浩徳, 三森 功士

    第19回　大分最少侵襲治療研究会  2014.10 

    　More details

    Event date： 2014.10

    Language：Japanese  

    Venue：大分   Country：Japan  

    対象は、経皮的治療困難や切除不能HCCを有する、ミリプラチン使用マイクロバルーン閉塞下TACE（MPT-B-TACE）が初回の４４例（男性28例女性16例、平均年齢74.2歳、平均腫瘍径2.8㎝, 腫瘍個数1個/2個/3個/多発: 29/ 8/3/4）。局所制御、有害事象を後視法的に比較検討した。MPT-B-TACEは、区域レベルでバルーン拡張下にミリプラ＋リピオドール注入後、ジェルパートで塞栓した。標的結節治療効果度で良好な初期治療効果(TE3,4)が得られた症例90.9%。局所制御率3M/6M: 88.6%/68.3%、無再発期間中央値は、9.1Mであった。腫瘍径2㎝以下、腫瘍個数3個以下の症例では、有意に局所制御率が高かった。CTCAEver3.0での有害事象は、Grade2胆のう炎2例認めた。MPT-B-TACEは、有害事象は許容範囲内で、比較的良好な中期治療成績が得られていると考えられる。

  • Comparison of the local control effects of microballoon-occluded transarterial chemoembolization using miriplatin and TACE using epirubicin for hepatocellular carcinoma: a retrospective study of 65 cases

    Masakazu Hirakawa, Wataru todoroki, S Tsuruta, K Miyajima, Hiroshi Honda

    第43回　日本IVR学会総会　IVR2014  2014.6 

    　More details

    Event date： 2014.6

    Language：Japanese  

    Venue：奈良   Country：Japan  

    目的：肝細胞癌(HCC)に対するミリプラチン使用マイクロバルーン閉塞下TACE (balloon-occluded transarterial chemoembolization: MPT-B-TACE)とエピルビシン使用TACE（EPIR-TACE）の治療成績について報告する。対象・方法：対象は、経皮的治療および切除不能HCCを有する65例で、MPT-B-TACE 群は40例(男：女25:15; 平均年齢73.4 歳)、EPIR-TACE群は25例（男：女15:10; 平均年齢72.2 ±1.7 years）について、局所制御、有害事象を後視法的に比較検討した。MPT-B-TACEは、マイクロバルーンカテーテルを区域レベルあるいはその遠位まで誘導し、バルーン拡張後、加温したミリプラ＋リピオドール suspension注入後、ジェルパートにて塞栓した。EPIR-TACEは、通常通りのTACEを行った。治療効果は、原発性肝癌取扱い規約　標的結節治療効果度で画像評価を行った。局所再発率を、Kaplan-Meier法、Log rank検定で比較検討した。有害事象は、CTCAEv3.0で評価した。結果：治療効果は、MPT-B-TACE（TE4 or TE3が得られた症例92%）が、EPIR-TACE（76%）より有意に高かった(P=0.02)。全症例での局所再発率は、MPT-B-TACEが、EPIR-TACEより有意に低かった(P<0.05)。サブグループ解析では、単発HCCの症例のみ、2㎝以下のHCCの各群での局所再発率は、MPT-B-TACEが、EPIR-TACEより有意に低かった(P<0.05)。有害事象については、各治療間で有意差は認めなかった。結論：MPT-B-TACEは、EPIR-TACEより、高い治療効果が得られる可能性が示唆された。

  • Local control effects of microballoon-occluded transarterial chemoembolization using miriplatin for hepatocellular carcinoma : a retrospective comparison of TACE using epirubicin International conference

    Masakazu Hirakawa, Katsumi Sakamoto, Kazushige Atsumi, Wataru Todoroki, Kimitaka Miyajima, Asayama Yoshiki, Akihiro Nishie, Hiroshi Honda

    The 11th Asia Pacific Congress of Cardiovascular and Interventional Radiology  2014.5 

    　More details

    Event date： 2014.5

    Language：English  

    Venue：Singapore general hospital   Country：Singapore  

    Objective: The aim of this study is to compare the local control effects of microballoon-occluded transarterial chemoembolization (B-TACE) using miriplatin (MPT) and that of TACE using epirubicin (EPIR) for hepatocellular carcinoma (HCC).MATERIALS AND METHODS: 55 HCC cases were treated with TACE using EPIR or MPT. 30 patients (MPT-B-TACE group: 20 men, 10 women; mean age 74.4years) were treated with B-TACE using MPT, and 25 patients (EPIR-TACE group: 15 men, 10 women; mean age 72.2) were treated with TACE using EPIR. The local control rate (modified Response Evaluation Criteria in Solid Tumors [mRECIST]), time to treatment failure (Kaplan-Meier and log-rank test) and adverse events (AEs)were evaluated. RESULTS: There were no significant differences in gender, age, etiology of chronic liver disease, Child-Pugh class, and tumor size among each group. The rate of tumor multiplicity for the EPI-TACE group tended to be higher than those for the MPT-B-TACE group. Overall incidence of AEs was not significantly different between each group. According to the mRECIST criteria, the objective response rate, including complete response and partial response, in the MPT-B-TACE group (90%) was significantly higher than that in the EPIR-TACE group (76%, p=0.02). Overall local recurrence in the MPT-B-TACE group was significantly lower than in the EPIR-TACE (p =0.0065). Excluding multiple HCC cases, also, the local recurrence in the MP T-B-TACE group was significantly lower than in the EPIR-TACE group (p=0.0015).CONCLUSION: B-TACE using miriplatin was associated with an increased objective response rate, low local recurrence rate and comparable adverse effects compared to TACE using epirubicin.

  • Comparison of the local control effects of microballoon-occluded transarterial chemoembolization (TACE) with miriplatin and TACE with epirubicin for hepatocellular carcinoma

    Masakazu Hirakawa, Katsumi Sakamoto, Kazushige Atsumi, Wataru Todoroki, Hiroshi Honda

    The 73rd Annual Meeting of the Japan Radiological Society  2014.4 

    　More details

    Event date： 2014.4

    Language：English  

    Venue：横浜   Country：Japan  

    OBJECTIVE
    This study aimed to compare the local control effects of microballoon-occluded transarterial chemoembolization (B-TACE) with miriplatin (MPT) and those of TACE with epirubicin (EPIR) for hepatocellular carcinoma (HCC).
    MATERIALS AND METHODS
    Fifty-five HCC cases were treated with TACE using EPIR or MPT. Thirty patients (20 men, 10 women; mean age, 74.4 years) were treated using B-TACE with MPT (the MPT-B-TACE group), and 25 patients (15 men, 10 women; mean age, 72.2 years) were treated using TACE with EPIR (the EPIR-TACE group). The local control rates (modified Response Evaluation Criteria in Solid Tumors [mRECIST]), time to treatment failures (Kaplan-Meier and log-rank tests), and adverse events (AEs) were evaluated.
    RESULTS
    There were no significant differences in gender, age, chronic liver disease etiology, Child-Pugh class, and tumor size between the groups. The tumor multiplicity rate of the EPIR-TACE group was higher than that of the MPT-B-TACE group. The overall AE incidence did not significantly differ between the groups. According to the mRECIST, the objective response rate including complete and partial responses, in the MPT-B-TACE group (90%) was significantly higher than that in the EPIR-TACE group (76%). Overall, local recurrences in the MPT-B-TACE group were significantly lower than in the EPIR-TACE group (p < 0.05). Excluding multiple HCC cases, the local recurrence rate in the MP T-B-TACE group was significantly lower than in the EPIR-TACE group (p < 0.05).
    CONCLUSION
    MPT-B-TACE was associated with a higher objective response rate and lower local recurrence rate than EPIR-TACE, and both showed similar adverse effects.

  • Comparison of the local control effects of microballoon-occluded transarterial chemoembolization using miriplatin and TACE using epirubicin for hepatocellular carcinoma: a retrospective study of 50cases International conference

    Masakazu Hirakawa, Katsumi Sakamoto, Kazushige Atsumi, Wataru Todoroki, Kimitaka Miyajima, Yoshiki Asayama, Akihiro Nishie, Hiroshi Honda

    The Society of Interventional Radiology will hold its 39th Annual Scientific Meeting  2014.3 

    　More details

    Event date： 2014.3

    Language：English  

    Venue：San Diego   Country：United States  

    PURPOSE: The aim of this retrospective study is to compare the local control effects of microballoon-occluded transarterial chemoembolization (B-TACE) using miriplatin (MPT) and that of TACE using epirubicin (EPIR) for hepatocellular carcinoma (HCC).
    MATERIALS AND METHODS: Between January 2012 and 2013, 50 HCC cases were treated with TACE using EPIR or MPT. 25 patients (MPT-B-TACE group: 18 men, 7 women; mean age 74.8 ±1.8 years) were treated with B-TACE using MPT, and 25 patients (EPIR-TACE group: 15 men, 10 women; mean age 72.2 ±1.7 years) were treated with TACE using EPIR. The local control rate (modified Response Evaluation Criteria in Solid Tumors [mRECIST]), time to treatment failure (Kaplan–Meier and log–rank test) and adverse events (AEs) were evaluated (CTACAE 3.0).
    RESULTS: There were no significant differences in gender, age, etiology of chronic liver disease, Child–Pugh class, and tumor size among the two groups. The rate of tumor multiplicity for the EPI-TACE group tended to be higher than those for the MPT-B-TACE group.
    No serious adverse events were observed in either group. Overall incidence adverse events was not significantly different between the MPT-B-TACE group (64%) and the EPIR-TACE group (68%, p=0.575). According to the mRECIST criteria, the objective response rate, including complete response (CR) and partial response (PR), in the MPT-B-TACE group (90%) was significantly higher than that in the EPIR-TACE group (76%, p=0.02). Overall local recurrence in the MPT-B-TACE group was significantly lower than in the EPIR-TACE (p=0.0065). Excluding multiple HCC cases, also, the local recurrence in the MPT-B-TACE group was significantly lower than in the EPIR-TACE group (p=0.0015).
    CONCLUSION: B-TACE using miriplatin was associated with an increased objective response rate, low local recurrence rate and comparable adverse effects compared to TACE using epirubicin.

  • Comparison of the local control effects of microballoon-occluded transarterial chemoembolization using miriplatin and TACE using epirubicin for hepatocellular carcinoma International conference

    Masakazu Hirakawa, Katsumi Sakamoto, Kazushige Atsumi, Asayama Yoshiki, Akihiro Nishie, Hiroshi Honda

    26th EUROPEAN CONGRESS OF RADIOLOGY  2014.3 

    　More details

    Event date： 2014.3

    Language：English  

    Venue：Vienna   Country：Australia  

    PURPOSE: The aim of this retrospective study is to compare the local control effects of microballoon-occluded transarterial chemoembolization (B-TACE) using miriplatin (MPT) and that of TACE using epirubicin (EPIR) for hepatocellular carcinoma (HCC).
    MATERIALS AND METHODS: Between January 2012 and January 2013, 39 HCC cases were treated with TACE using EPIR or MPT. 14 patients (MPT-B-TACE group: 9 men, 5 women; mean age 70.4 ±2.0 years) were treated with B-TACE using MPT, and 25 patients (EPIR-TACE group: 15 men, 10 women; mean age 72.2 ±1.7 years) were treated with TACE using EPIR. The local control rate (modified Response Evaluation Criteria in Solid Tumors [mRECIST]), time to treatment failure (Kaplan–Meier and log–rank test) and adverse events (AEs) were evaluated (CTACAE 3.0).
    RESULTS: There were no significant differences in gender, age, etiology of chronic liver disease, Child–Pugh class, and tumor size among the two groups. The rate of Tumor multiplicity and selective TACE procedure for the EPI-TACE group was significantly higher than those for the MPT-B-TACE group (P<0.05).
    No serious adverse events were observed in either group. Overall incidence adverse events was not significantly different between the MPT-B-TACE group (50%) and the EPIR-TACE group (49%, p=0.575). According to the mRECIST criteria, the objective response rate, including complete response (CR) and partial response (PR), in the MPT-B-TACE group (92.9%) was significantly higher than that in the EPIR-TACE group (76%, p=0.02). Overall local recurrence in the MPT-B-TACE group was significantly lower than in the EPIR-TACE (p=0.05). Excluding multiple HCC cases, also, the local recurrence in the MPT-B-TACE group was significantly lower than in the EPIR-TACE group (p=0.04).
    CONCLUSION: B-TACE using miriplatin was associated with an increased objective response rate, low local recurrence rate and comparable adverse effects compared to TACE using epirubicin.

  • 肝細胞癌に対するマイクロバルーンカテーテルを使用した新たな血管内治療への挑戦

    平川 雅和, 杉町 圭史, 轟木渉, 宮嶋公貴, 鶴田悟, 酒井浩徳, 三森 功士

    平成25年度　別府市医師会学術講演会  2014.2 

    　More details

    Event date： 2014.2

    Language：Japanese  

    Venue：別府市   Country：Japan  

    肝細胞癌に対しては、外科手術、経皮的治療、血管内治療の3つの主な治療法がある。血管内治療は、他2治療が困難な症例に対して、動脈内に抗癌剤や塞栓物質を注入する、いわゆる動脈化学塞栓療法（TACE）であり、その有効性を報告する文献も多い。TACEでは、マイクロカテーテルを用いた選択的TACEが主流であったが、近年、マイクロカテーテルの先端に、小さなバルーンを有するカテーテルが、肝細胞がんの治療に応用されつつある。肝動脈内にて、バルーン拡張し、肝動脈を一時的閉塞状態にすることにより、肝動脈、門脈、肝静脈の血行動態が変化する。肝細胞癌は、動脈多血性腫瘍かつ門脈や肝静脈に腫瘍血流は潅流するため、肝動脈閉塞下の血行動態の変化状態では、通常のTACEよりも、肝細胞癌に対して良好な薬剤集積が認められ、我々も優れた局所制御能を実感している。
    今回、肝細胞癌患者様の予後改善に微力ながら寄与すべく、マイクロバルーン閉塞下TACE (Microballoon-occluded-TACE: B-TACE)の治療法の紹介と治療成績、可能性について報告させていただく。

  • HCCに対するミリプラチン使用マイクロバルーン閉塞下TACEとエピルビシン使用TACEの治療成績に関する後視法的検討 －どのような症例にミリプラチンB-TACEが有効か？－

    平川 雅和, 杉町 圭史, 轟木渉, 宮嶋公貴, 鶴田悟, 酒井浩徳, 三森 功士

    動注化学療法フォーラム2014  2014.2 

    　More details

    Event date： 2014.2

    Language：Japanese  

    Venue：福岡   Country：Japan  

  • HCCに対するミリプラチン使用マイクロバルーン閉塞下TACEとエピルビシン使用TACEの局所制御に関する検討

    平川 雅和, 杉町 圭史, 轟木渉, 宮嶋公貴, 鶴田悟, 酒井浩徳, 三森 功士

    大分肝臓疾患研究会  2014.1 

    　More details

    Event date： 2014.1

    Language：Japanese  

    Venue：大分   Country：Japan  

    肝細胞癌に対するミリプラチン使用マイクロバルーン閉塞下TACE (MPT-B-TACE)とエピルビシン使用TACE（EPIR-TACE）の治療成績について報告する。対象は、経皮的治療および切除不能HCCを有する50例で、MPT-B-TACE group25例、EPIR-TACE group25例について、局所制御、有害事象を後視法的に比較検討した。MPT-B-TACEは、マイクロバルーンカテーテルを区域レベルまで誘導し、バルーン拡張後、ミリプラ＋リピオドール、ジェルパートを注入した。治療効果（TE4 or TE3が得られた症例）は、MPT-B-TACEが、EPIR-TACEより有意に高かった。全症例、単発HCCの症例での局所再発率は、MPT-B-TACEが、EPIR-TACEより有意に低かった。有害事象については、有意差は認めなかった。MPT-B-TACEは、良好な局所制御が得られる可能性がある。

  • 腹腔動脈狭窄合併肝細胞癌に対してマイクロバルーン閉塞下TACEを施行した2例

    轟木渉, 平川 雅和, 鶴田悟, 宮嶋公貴

    日本IVR学会　九州地方会  2013.12 

    　More details

    Event date： 2013.12

    Language：Japanese  

    Venue：福岡   Country：Japan  

    正中弓状靭帯によるものと考えられる腹腔動脈起始部狭窄合併肝細胞癌に対してマイクロバルーン閉塞下TACE（B-TACE）を施行した2例を報告する。症例1は60歳代男性。肝左葉外側区の2㎝のHCCに対して、TACEが依頼された。腹腔動脈起近位部に狭窄を認めたが、吸気時にわずかに開存する腹腔動脈より、マイクロバルーンカテーテルを慎重に挿入し、選択的に左肝動脈にカテーテルを誘導した。ミリプラチンを用いたB-TACEを施行し、5か月後無再発生存中である。症例2は70歳代男性。肝右葉切除後3.5㎝の再発肝細胞癌に対してTACE依頼された。腹腔動脈よりマイクロバルーンカテーテルの挿入が困難であったため、マイクロバルーンカテーテルを、SMAより膵アーケードを介して、中肝動脈まで誘導した。ミチプラリンを用いたB-TACEを施行し良好なリピオドール沈着が得られた。3か月後無再発生存中である。

  • 肝細胞癌に対するミリプラチン使用マイクロバルーン閉塞下TACEとエピルビシン使用TACEの治療成績に関する検討

    平川 雅和, 轟木渉, 鶴田悟, 宮嶋公貴

    第36回　日本IVR学会九州地方会  2013.12 

    　More details

    Event date： 2013.12

    Language：Japanese  

    Venue：福岡   Country：Japan  

    目的： HCCに対するミリプラチン使用マイクロバルーン閉塞下TACE (MPT-B-TACE)とエピルビシン使用TACE（EPIR-TACE）の治療成績を報告する。方法： MPT-B-TACE 群20例、EPIR-TACE群25例について、局所制御、有害事象を比較検討した。治療効果は、標的結節治療効果度で、局所再発率は、Kaplan-Meier法で、有害事象は、CTCAEv3.0で比較検討した。結果：患者背景で、多発症例、亜区域TACE症例に有意差を認めた。治療効果は、MPT-B-TACE（TE4 or TE3症例92%）が、EPIR-TACE（76%）より有意に高かった。全症例、単発HCCの症例でも局所再発率は、MPT-B-TACEが、EPIR-TACEより有意に低かった。有害事象は、有意差は認めなかった。結論：MPT-B-TACEは、EPIR-TACEより、高い治療効果が得られる可能性がある。

  • 肝細胞癌に対するミリプラチン使用マイクロバルーン閉塞下TACEとエピルビシンTACEの治療成績の検討

    平川 雅和

    第18回　大分最少侵襲治療法研究会  2013.11 

    　More details

    Event date： 2013.11

    Language：Japanese  

    Venue：大分市   Country：Japan  

    対象は、経皮的治療や切除不能HCCの39例。MPT-B-TACE groupは14例、EPIR-TACE groupは25例について、局所制御、有害事象を後視法的に比較検討した。MPT-B-TACEは、区域レベルでバルーン拡張下にミリプラ＋リピオドール注入後、ジェルパートで塞栓した。EPIR-TACEは、一般的TACEを施行。結果：患者背景で、EPIR-TACE groupが、 MPT-B-TACEより有意に多発症例が多かった。標的結節治療効果度で良好な初期治療効果が得られた症例は、MPT-B-TACEが、EPIR-TACEより有意に高かった。全症例および、単発HCCの症例のみでの局所再発率は、MPT-B-TACEが、EPIR-TACEより有意に低かった。有害事象については、各グループ間で有意差は認めなかった。MPT-B-TACEは、EPIR-TACEより、高い治療効果が得られる可能性がある。

  • 腎血管筋脂肪腫に対してマイクロバルーン閉塞下TAEを施行した1例

    清澤恵理子, 平川 雅和, 渡辺秀幸

    日本IVR学会  2013.5 

    　More details

    Event date： 2013.5

    Language：Japanese  

    Venue：軽井沢   Country：Japan  

    A case of renal angiomyolipoma treated by Microballoon-occluded transarterial embolization

  • ミリプラチン使用マイクロバルーン閉塞下TACEの初期治療経験

    平川 雅和, 坂本 勝美, 渥美 和重, 西江 昭弘, 浅山 良樹, 本田 浩

    日本IVR学会  2013.5 

    　More details

    Event date： 2013.5

    Language：Japanese  

    Venue：軽井沢   Country：Japan  

    Balloon-occluded Transarterial Chemoembolization with Miriplatin for Hepatocellular Carcinoma: Preliminary Clinical Experience

  • 切除不能肝内胆管細胞癌に対するGEM併用CDDP肝動脈化学塞栓術の予後予測因子に関する検討

    平川 雅和, 坂本 勝美, 渥美 和重, 西江 昭弘, 浅山 良樹, 牛島 泰宏, 本田 浩

    第72回　日本医学放射線学会総会  2013.4 

    　More details

    Event date： 2013.4

    Language：Japanese  

    Venue：横浜　パシフィコ横浜   Country：Japan  

    Analysis of the Response and Prognostic Factors after Cisplatin-based Transcatheter Arterial Chemoembolization along with systemic chemotherapy with Gemcitabine in the palliative Treatment of Unresectable intrahepatic Cholangiocarcinoma

  • Analysis of the response and prognostic factors after cisplatin-based transcatheter arterial chemoembolization along with systemic chemotherapy with gemcitabine in the palliative treatment of unresectable intrahepatic cholangiocarcinoma International conference

    平川 雅和, 坂本 勝美, 渥美 和重, 西江 昭弘, 浅山 良樹, 本田 浩

    European congress of Radiology  2013.3 

    　More details

    Event date： 2013.3

    Language：English  

    Venue：Vienna   Country：Austria  

    PURPOSE: To evaluate the effectiveness of cisplatin-based transcatheter arterial chemoembolization (TACE) along with systemic chemotherapy with gemcitabine in the palliative treatment of unresectable intrahepatic cholangiocarcinoma (ICC), and to identify factors affecting clinical outcome.

    MATERIALS AND METHODS: The present study was approved by the institutional review board, and written informed consent was obtained from all patients.
    Between 2007 and 2011, 13 patients (5 men, 8 women; mean age 70.4 ±2.0 years) with unresectable ICC underwent cisplatin-based TACE alongside systemic chemotherapy with gemcitabine. Mean tumor size was 9.8 ± 0.7 cm (range, 6.7–15 cm).The adverse effects (AEs), survival rate and prognostic factors of patient survival were evaluated.
    RESULTS: The mean TACE sessions and cycles of systemic chemotherapy were 3.5 (range: 1-7) and 6.2 (range: 4 -11), respectively. Combined TACE and systemic chemotherapy were followed by few Grade 3 hematological AEs, without G4 AEs, according to CTACAE 3.0. No deaths and no acute liver failure occurred after TACE. According to the RECIST criteria, 23% (3/13) of patients achieved partial response and 46% (6/13) stabilization of disease. The Kaplan- Meier survival analysis showed that the median overall survival and median progression-free survival were 14 [95%CI: 9-16] and 8 [95%CI: 4-9] months, respectively. Results from multivariable Cox regression analyses confirmed that tumor number (hazard ratio [HR], 8.33; P = .004) and Child-Pugh class (HR, 5.34; P = .02) were the independent factors associated with patient survival duration.

    CONCLUSION: Cisplatin-based TACE along with systemic chemotherapy with gemcitabine is a safe and effective treatment for patients with unresectable ICC. Multiple tumors and Child-Pugh class B were poor prognostic factors for determining the patient survival period after treatment for unresectable ICC.

  • 治療に難渋した慢性膵炎に伴った仮性動脈瘤破裂の1例

    平川雅和　・轟木渉・松尾享・添田博康

    第17回　大分最少侵襲治療研究会  2012.10 

    　More details

    Event date： 2012.10

    Venue：大分   Country：Japan  

    慢性膵炎に伴った仮性動脈瘤破裂に対して、２度のTAEを施行するも、最終的に手術にて止血され、治療に難渋した1症例を報告する。症例は50歳代男性。末期腎不全、アルコール性慢性膵炎で加療中、貧血進行を認めた。CTで膵仮性嚢胞内に脾動脈瘤を認めた。脾動脈本幹より仮性動脈瘤を認め、金属コイルによるisolationを施行し、仮性動脈瘤の血栓化と貧血の改善得た。1年4カ月後、再度貧血進行、CTで胃背側の血腫と造影剤の血管外漏出を認めた。左肝動脈より分岐する副左胃動脈より側副血管を介して仮性動脈瘤の描出を認め、NBCAでTAE施行したが、側副血管レベルにて近位塞栓となった。ほか右胃大網動脈や左胃動脈より側副血管を介した仮性動脈瘤を認め、スポンゼル細片にてTAEを施行したが、近位塞栓状態で終了した。Vital安定と貧血の軽度改善を一時的に得たが、翌日再出血を認め、膵尾部切除および胃全摘術が施行され、１か月後生存中である。

  • 前立腺癌に対する強度変調放射線治療の初期経験

    渥美和重、坂本勝美、吉留郷志、穴井重男、平川雅和、塩山善之、中村和正、本田浩

    第175回　日本医学放射線学会九州地方会  2012.6 

    　More details

    Event date： 2012.6

    Venue：鹿児島   Country：Japan  

  • マイクロバルーンカテーテルによるdistal occlusion下のTACEが奏功した肝細胞癌の一例　

    轟木　渉、　大塚　誠、　添田　博康, 鶴田　悟, 平川　雅和

    第175回　日本医学放射線学会九州地方会  2012.6 

    　More details

    Event date： 2012.6

    Venue：鹿児島   Country：Japan  

  • 切除不能肝内胆管細胞癌に対するゲムシタビン併用シスプラチン肝動脈化学塞栓術の検討

    平川雅和・坂本勝美・渥美和重・西江昭弘・浅山良樹・石神康生・牛島泰宏・柿原大輔・本田 浩

    第71回　日本医学放射線学会　総会  2012.4 

    　More details

    Event date： 2012.4

    Venue：横浜   Country：Japan  

    Efficacy of Cisplatin-based Transcatheter Arterial Chemoembolization along with systemic chemotherapy with Gemcitabine in the Treatment of Unresectable intrahepatic Cholangiocarcinoma

  • 当院における高精度放射線治療について

    渥美和重、坂本勝美、平川雅和

    平成23年度　別府市医師会学術講演会  2012.2 

    　More details

    Event date： 2012.2

    Venue：別府   Country：Japan  

  • 肝細胞癌の胸壁転移破裂による出血性ショックに対してTAEで救命した1例

    平川雅和・永尾英毅 ・﨑山祐美子 ・添田博康

    第34回　日本IVR学会　九州地方会  2011.12 

    　More details

    Event date： 2011.12

    Venue：福岡   Country：Japan  

  • Favorable predictors for Quality of Life after Self-Expandable Metallic Stent Placement in patients with malignant Inferior Vena Cava Syndrome International conference

    Masakazu Hirakawa, K Nakamura, M Miyasaka, A Nishie , K Ishigami , H Honda

    97th Scientific Assembly and Annual Meeting of Radiological Society of North America RSNA（北米放射線学会）  2011.12 

    　More details

    Event date： 2011.11 - 2011.12

    Venue：Chicago   Country：United States  

  • 胃Plexiform fibromyxomaの一例

    坂本勝美、平川雅和、渥美和重

    別府胃腸会  2011.11 

    　More details

    Event date： 2011.11

    Venue：別府   Country：Japan  

  • 膵頭部癌に対する膵頭十二指腸切除術後出血に対するTAE後に広範な肝膿瘍を生じた1例

    平川 雅和・坂本勝美・渥美和重 柴田 浩平

    2011　大分最少侵襲治療研究会  2011.11 

    　More details

    Event date： 2011.11

    Venue：大分   Country：Japan  

  • Percutaneous vertebroplasty for osteoporotic compression fractures with large vs small intervertebral clefts: Which is pre-procedural favorable predictors of pain relief? International conference

    Masakazu Hirakawa, M.D. , Ph.D.1,2, Nobuo Kobayashi, M.D.1, Mitsutomi Ishiyama, M.D.1, Sokun Fuwa, M.D.1, Yukihisa Saida M.D., Ph.D.1, Hiroshi Honda, M.D., Ph.D.3 Yuji Numaguchi, M.D., Ph.D.1

    ASNR 49th ANNUAL MEETING & THE FOUNDATION OF THE ASNR SYMPOSIUM 2011  2011.6 

    　More details

    Event date： 2011.6 - 2012.6

    Venue：Seattle   Country：United States  

  • 骨粗鬆症性圧迫骨折に対する経皮的椎体形成術後の除痛に関与する予後測因子の検討

    平川 雅和, 小林 信雄, 石山 光富, 不破 相勲, 齋田 幸久, 本田 浩, 沼口 雄治.

    第40回日本IVR学会総会  2011.5 

    　More details

    Event date： 2011.5

    Venue：青森   Country：Japan  

  • 骨粗鬆症性圧迫骨折に対する経皮的椎体形成術後の除痛に関与する予後測因子の検討

    平川 雅和, 小林 信雄, 石山 光富, 不破 相勲, 齋田 幸久, 本田 浩, 沼口 雄治

    第4回脊椎IVRフォーラム  2011.2 

    　More details

    Event date： 2011.2

    Venue：東京   Country：Japan  

  • 悪性肝腫瘍によるIVC狭窄に対して金属ステントを留置した2例

    平川 雅和　　宮坂 光俊　　柴田 浩平　中村 和正

    日本IVR学会　九州地方会  2010.12 

    　More details

    Event date： 2010.12

    Venue：福岡   Country：Japan  

  • Radiosensitization by L-arginine in human hepatoma cell line HepG2 in vitro and in vivo International conference

    Masakazu Hirakawa, K Nakamura, M Miyasaka,A Nishie, K Iishigami, H Honda

    RSNA（北米放射線学会）  2010.11 

    　More details

    Event date： 2010.11 - 2010.12

    Venue：Chicago   Country：United States  

  • Radiological findings as favorable predictors of pain relief in patients with osteoporotic compression fractures after percutaneous vertebroplasty: a retrospective study of 156 cases. International conference

    Masakazu Hirakawa, N Kobayashi, M Ishiyama, S Fuwa, Y Saida, H Honda, Y Numaguchi

    RSNA  2010.11 

    　More details

    Event date： 2010.11 - 2010.12

    Presentation type：Oral presentation (general)  

    Venue：Chicago   Country：United States  

  • 悪性肝腫瘍によるIVC狭窄に対して金属ステントを留置した2例

    平川 雅和　　宮坂 光俊　　柴田 浩平 中村 和正

    大分最少侵襲治療研究会  2010.9 

    　More details

    Event date： 2010.9

    Venue：大分   Country：Japan  

  • 生体肝移植症例における肝細胞癌の画像診断能： Dynamic CT, MRI, CTHA/CTAPの比

    平川 雅和, 宮坂 光俊, 中村 和正

    第68回　別府胃腸会  2010.5 

    　More details

    Event date： 2010.5

    Venue：別府   Country：Japan  

  • Efficacy of Preoperative Transcatheter Arterial Chemoembolization Along With Systemic Chemotherapy in the Treatment of Unresectable Hepatoblastoma in Children International conference

    Masakazu Hirakawa, Tsuyoshi Tajima, Akihiro Nishie, Yoshiki Asayama, Kousei Ishigami, Daisuke Kakihara, Daisuke Okamoto, and Hiroshi Honda

    2009　Radiogical Society of North America Scientific Assembly and Annual Meeting  2009.11 

    　More details

    Event date： 2009.11 - 2009.12

    Venue：McCormick Place Chicago, USA   Country：United States  

    Efficacy of Preoperative Transcatheter Arterial Chemoembolization Along With Systemic Chemotherapy in the Treatment of Unresectable Hepatoblastoma in Children

  • 小児肝芽腫に対するTACEの安全性と治療成績

    平川雅和, 田嶋 強,　西江昭弘,　浅山良樹,　石神康生,牛島泰宏,　柿原大輔,　岡本大祐, 藤田展宏,田尻達郎,　田口智章, 本田 浩

    第38回　日本IVR学会総会  2009.5 

    　More details

    Event date： 2009.5

    Venue：ハイアットリージェンシー　大阪   Country：Japan  

    Efficacy of Preoperative Transcatheter Arterial Chemoembolization Along With Systemic Chemotherapy in the Treatment of Unresectable Hepatoblastoma in Children

  • 小児肝芽腫に対するTACEの安全性と治療成績

    平川雅和　田嶋 強,　西江昭弘,　浅山良樹,　石神康生,　牛島泰宏,　柿原大輔,　岡本大祐, 藤田展宏,田尻達郎,　田口智章本田 浩

    第６８回日本医学放射線学会総会  2009.4 

    　More details

    Event date： 2009.4

    Venue：横浜   Country：Japan  

  • Efficacy of Transarterial Therapy for Hepatocellular Carcinoma in the Caudate Lobe International conference

    Masakazu Hirakawa*, Tsuyoshi Tajima, Kengo Yoshimitsu, Hiroyuki Irie, Akihiro Nishie, Kousei Ishigami, Yasuhiro Ushijima, Daisuke Okamoto, and Hiroshi Honda

    94th Scientific Assembly and Annual Meeting of Radiological Society of North America (北米放射線学会）  2008.12 

    　More details

    Event date： 2008.11 - 2008.12

    Venue：Chiacago   Country：United States  

  • 子宮頸癌患者における移動卵巣術後のMDCT所見

    平川雅和, 吉満研吾, 入江裕之, 田嶋強,石神康生，牛島泰宏，岡本大佑, 矢幡秀昭、本田浩

    第66回　日本医学放射線学会学術集会  2007.4 

    　More details

    Venue：横浜   Country：Japan  

  • Transcatheter Arterial Embolization of Idiopathic Visceral Artery Aneurysms: Technical and Clinical Outcomes International conference

    Masakazu Hirakawa, Tsuyoshi Tajima, Kengo Yoshimitsu1), Akihiro Nishie, Kousei Ishigami, Yasuhiro Ushijima, 　Daisuke Okamoto, Takeshi Kamitani and Hiroshi Honda

    The　10th International Symposium on Interventional Radiology  2008.5 

    　More details

    Venue：Karuizawa   Country：Japan  

  • 尾状葉肝細胞癌に対する経血管治療の治療成績

    平川雅和, 田嶋 強, 吉満研吾, 入江 裕之, 西江昭弘, 石神康生, 牛島泰宏, 岡本大佑, 本田 浩

    日本医学放射線学会  2008.4 

    　More details

    Venue：横浜   Country：Japan  

  • Uterine arterial embolization for cervical ectopic pregnancy with vaginal bleeding Technique, Complication, Clinical outcome and Follow-up International conference

    Masakazu Hirakawa, Tsuyoshi Tajima, Kengo Yoshimitsu, Hiroyuki Irie, Akihiro Nishie, Kousei Ishigami, Yasuhiro Ushijima, Daisuke Okamoto, Hideaki Yahata*, Norio Wake and Hiroshi Honda.

    RSNA　93 Scientific Assembly and Annual Meeting of Radiological Society of North America 北米放射線学会  2007.11 

    　More details

    Venue：Chicago   Country：United States  

  • Transcatherter Arterial Embolization for Severe Arterioportal Fistula: Effectiveness, Complication and Clinical outcome International conference

    Masakazu Hirakawa, Tsuyoshi Tajima, Kengo Yoshimitsu, Hiroyuki Irie, Akihiro Nishie, Kousei Ishigami, Yasuhiro Ushijima, Daisuke Okamoto and Hiroshi Honda

    93 Scientific Assembly and Annual Meeting of Radiological Society of North America  2007.11 

    　More details

    Venue：Chicago   Country：United States  

  • マイクロバルーン閉塞下シスプラチン動注併用DEB-TACEにて治療した肝細胞癌の1例

    平川雅和,山之内寅彦,坂本勝美,脇山浩明,松本圭司,井上昭宏

    第22回大分最小侵襲治療研究会  2017.11 

    　More details

    Event date： 2017.11

    Language：Japanese  

    Venue：大分   Country：Japan  

    シスプラチン含浸球状塞栓物質使用TACE（DEB-TACE）にて治療した肝細胞癌症例を報告する。症例は60歳代男性。B型慢性肝炎にて経過観察中に肝腫瘤にて紹介となった。肝左葉に胆管浸潤を有する多血性肝細胞癌を認めた。エピルビシン含浸DC beadsにて初回治療を施行し、辺縁および胆管浸潤部分に残存病変を認めた。次に、ミリプラチン使用B-TACCEを施行し、残存病変に比較的良好なLipiodol沈着を認めたが、経過観察CTにて、Vascularityの多くない腫瘍および門脈本幹に及ぶ腫瘍栓を認めた。残存病変に対してマイクロバルーン閉塞下シスプラチン動注後、引き続きシスプラチン含浸ヘパスフィアにてDEB-TACEを行った。治療後のCTにて残存病変の縮小を認めたため、同様の治療を追加した。最終治療12ヵ月後CTにて確認される肝細胞癌は認めず、良好な局所制御が得られていると考えられる。

  • 食道癌化学放射線療法における予後因子としてのFDG-PETの有用性

    渥美和重・中村和正・塩山善之・佐々木智成・大賀才路・阿部光一郎・坂本勝美・平川雅和・平田秀紀・本田 浩

    第71回　日本医学放射線学会　総会  2012.4 

    　More details

    Event date： 2012.4

    Venue：横浜   Country：Japan  

  • CTコロノグラフィーが3型大腸癌の診断に有用であった１例

    宮坂 光俊, 平川 雅和, 中村 和正

    第172回　日本医学放射線学会　九州地方会  2011.2 

    　More details

    Event date： 2011.2

    Venue：宮崎市   Country：Japan  

  • CTガストログラフィーが病変の範囲診断に有用であった牛角胃におけるスキルス胃癌の二例

    宮坂 光俊, 平川 雅和, 中村 和正

    第16回　別府・県北消化器内視鏡懇話会  2010.10 

    　More details

    Event date： 2010.10

    Country：Japan  

  • 特徴的なCT画像所見を呈した腸管出血性大腸菌（O157）感染症の２例

    宮坂 光俊, 平川 雅和, 中村 和正

    第229回　別府胃腸会  2010.8 

    　More details

    Event date： 2010.8

    Venue：別府市   Country：Japan  

  • Transcatheter arterial embolization of idiopathic visceral artery aneurysms: Technical and Clinical outcomes International conference

    Masakazu Hirakawa, Tsuyoshi Tajima, Kengo Yoshimitsu, Akihiro Nishie, Kousei Ishigami, Yasuhiro Ushijima, Takeshi Kamitani, Daisuke Okamoto and Hiroshi Honda

    Society of Interventional Radiology (SIR)  2008.5 

    　More details

    Event date： 2008.5

    Presentation type：Oral presentation (general)  

    Venue：Karuizawa   Country：Japan  

  • 尾状葉肝細胞癌に対する経血管治療の治療成績

    平川雅和, 田嶋 強, 吉満研吾, 入江 裕之, 西江昭弘, 石神康生, 牛島泰宏, 岡本大佑, 本田 浩

    第67回　日本医学放射線学会  2008.4 

    　More details

    Event date： 2008.4

    Presentation type：Oral presentation (general)  

    Venue：横浜   Country：Japan  

  • Bellini duct carcinomaの3例

    平川　雅和、木村　正彦、坂井　修二、桑野　晴夫、本岡　慎、三好　真琴、小野　稔　豊島　里志　安東　定

    第141回　日本医学放射線学会九州地方会  1996.2 

    　More details

    Venue：鹿児島   Country：Japan  

  • 十二指腸球部病変と誤診したprolapsed gastric hyperplastic polypの3例

    平川　雅和、川元　健二、山田　義生、宇都宮　尚、増田　康治

    1996.10 

    　More details

    Venue：第143回　日本医学放射線学会九州地方会   Country：Japan  

  • 頚管妊娠に対する選択的子宮動脈塞栓術の治療成績と予後に関する検討

    平川雅和, 田嶋強、吉満研吾, 入江裕之, , 西江昭弘,石神康生, 牛島泰宏、岡本大佑, 矢幡秀昭, 和氣徳夫、本田浩

    第36回　日本IVR学会総会  2007.5 

    　More details

    Venue：金沢   Country：Japan  

  • 食道癌における新規ドライバー遺伝子候補PDCD10の同定と治療薬候補の選定(Identification of candidate driver gene PDCD10 and selection of therapeutic drug candidates in ESCC)

    平木 嘉樹, 増田 隆明, 本村 有史, 大樂 勝司, 阿部 正, 安東 由貴, 中野 祐輔, 細田 清孝, 巽 孝成, 甲斐 聖広, 津田 康雄, 長尾 吉泰, 米村 祐輔, 平川 雅和, 三森 功士

    日本癌学会総会記事  2023.9  (一社)日本癌学会

    　More details

    Language：English  

  • 放射線防護手袋の手指放射線防護能に関する比較検討(Comparison of radiation shielding effect to finger with Different Types of Radio-Protective Glove)

    平川 雅和, 甲斐 聖広, 本村 有史, 平木 嘉樹, 古屋 暁生

    日本インターベンショナルラジオロジー学会雑誌  2024.4  (一社)日本インターベンショナルラジオロジー学会

    　More details

    Language：English  

  • 放射線被曝防護手袋のIVR術者の手指被曝低減に関する臨床的検討(Clinical Evaluation of a Radio-Protective Glove for the Finger Exposure of the Interventional Radiologist: A Short-Term Study)

    Hirakawa Masakazu, Kai Satohiro, Motomura Yuushi, Hiraki Yoshiki, Furuya Atuo

    日本医学放射線学会学術集会抄録集  2024.3  (公社)日本医学放射線学会

    　More details

    Language：English  

  • 再発性膵癌による消化管出血に対し経皮経肝的に門脈ステントを留置した1例

    高尾 誠一朗, 平川 雅和, 本村 有史, 坂本 勝美, 武石 一樹, 大津 甫, 米村 祐輔, 三森 功士, 石神 康生

    Japanese Journal of Radiology  2023.2  (公社)日本医学放射線学会

    　More details

    Language：Japanese  

  • IVR施行時の眼球(水晶体)線量に対する水晶体用線量計と放射線防護デバイスの重要性(Importance of direct eye dosimeter and protective lead device for eye dose during IVR procedure)

    Hirakawa Masakazu, Nakatake Hiroshi, Matsuura Shuuji

    日本インターベンショナルラジオロジー学会雑誌  2022.5  (一社)日本インターベンショナルラジオロジー学会

    　More details

    Language：English  

▼display all

MISC

  • Dosimetry of Occupational Eye Lens Dose Using a Novel Direct Eye Dosimeter, DOSIRIS, during Interventional Radiology Procedures Reviewed

    Masakazu Hirakawa, Hiroshi Nakatake, Satoru Tsuruta, Shuji Matsuura, Yuushi Motomura, Yoshiki Hiraki, Koshi Mimori, Kousei Ishigami

    Interventional Radiology   2022.7

    　More details

    Language：English   Publishing type：Article, review, commentary, editorial, etc. (scientific journal)  

    In response to the recommendation by the International Commission on Radiological Protection to lower the equivalent eye dose limit, the Japanese Government in April 2021 lowered the equivalent dose limit for the eye lens for occupational exposure. A considerable number of interventional radiology operators are exposed to levels above the new limit. For this reason, a need exists to more accurately evaluate eye lens dose in interventional radiology operators by using a novel direct eye dosimeter, the DOSIRIS™ (IRSN, France), which is capable of measuring a 3-mm dose equivalent under protective glasses. The DOSIRIS is a thermoluminescent dosimeter that exhibits good energy dependence and better directional properties than other dosimeters. Dosimetry using DOSIRIS might be accurate and compatible with the latest regulations.

    DOI： https://doi.org/10.22575/interventionalradiology.2022-0005

  • エキスパートによるRSNAベストリポート：IVRの最新動向

    平川雅和

    インナービジョン　2月特集記事　株式会社インナービジョン   2019.2

    　More details

    Language：Japanese   Publishing type：Article, review, commentary, editorial, etc. (scientific journal)  

  • 当院におけるディーシービーズを用いた動脈化学塞栓療法の手技のポイント　九州大学病院別府病院編

    平川雅和

    2018.9

    　More details

    Language：Japanese   Publishing type：Article, review, commentary, editorial, etc. (scientific journal)  

  • IVRの被ばく　up-to-date　IVRの患者被ばく防護

    平川雅和

    日本インターベンショナルラジオロジー学会雑誌   2017.6

    　More details

    Language：Japanese   Publishing type：Article, review, commentary, editorial, etc. (scientific journal)  

  • 「AMULET Innovality」の使用経験

    Masakazu Hirakawa

    インナービジョン   2014.8

    　More details

    Language：Japanese   Publishing type：Article, review, commentary, editorial, etc. (scientific journal)  

  • 【画像ガイド下治療を支える手技と技術】画像下治療における被ばく低減

    平川 雅和

    映像情報Medical   56 ( 8 )   56 - 59   2024.7   （ ISSN:1346-1354 ）

    　More details

    Language：Japanese   Publisher：産業開発機構(株)  

  • 新規の眼水晶体用線量計DOSIRISによる直接測定を用いた、インターベンショナルラジオロジー手技下での眼水晶体への職業被ばく線量測定(Dosimetry of Occupational Eye Lens Dose Using a Novel Direct Eye Dosimeter, DOSIRIS, during Interventional Radiology Procedures)

    Hirakawa Masakazu, Nakatake Hiroshi, Tsuruta Satoru, Matsuura Shuji, Motomura Yuushi, Hiraki Yoshiki, Mimori Koshi, Ishigami Kousei

    Interventional Radiology   7 ( 2 )   40 - 43   2022.7

    　More details

    Language：English   Publisher：(一社)日本インターベンショナルラジオロジー学会  

  • Spectrum of unusual imaging findings of metastatic lesions from gastric cancer

    Ishigami K, Yoshimitsu K, Irie H, Tajima T, Nishie A, Hirakawa M, UshijimaY, Okamoto D, Ino A, Kiyosawa E, Sakai M, Hirata A, Honda H.

    Curr Med Imaging Rev 6(3): 171-177,   2010.5

    　More details

    Language：English   Publishing type：Article, review, commentary, editorial, etc. (scientific journal)  

  • 画像による悪性腫瘍の病期診断2010：膵

    石神 康生, 田嶋 強, 平川 雅和, 西江 昭弘, 浅山 良樹, 柿原 大輔, 中山 智博, 岡本大佑, 本田 浩

    臨床画像26(4):98-109.   2010.5

    　More details

    Language：Japanese   Publishing type：Article, review, commentary, editorial, etc. (scientific journal)  

  • 特集　この処置の直後 どう見る？ どう動く？1.検査関連： 血管造影直後 消化器外科NURSING　2005，10（9）：10-11

    平川雅和, 田嶋　強, 吉満研吾, 入江裕之, 本田 浩

    消化器外科NURSING　2005，10（9）：10-11   2005.9

    　More details

    Language：Japanese   Publishing type：Article, review, commentary, editorial, etc. (scientific journal)  

  • 特集 この処置の直後 どう見る？ どう動く？1.検査関連： MRIの直後

    石神康生, 吉満研吾, 入江裕之, 田嶋 強, 浅山良樹, 平川雅和, 柿原大輔, 本田 浩

    消化器外科NURSING   2005.5

    　More details

    Language：Japanese   Publishing type：Article, review, commentary, editorial, etc. (scientific journal)  

  • Steroid-induced osteonecrosis in refractory ulcerative colitis.

    Ito K, Inuo-Nakayama M, Matsumoto M, Kubokawa M, Sadamoto Y, Kubo H, Tanaka M, Harada N, Torigoshi K, Hirakawa M, Nawata H.

    Fukuoka Igaku Zasshi   2005.5

    　More details

    Language：Japanese   Publishing type：Article, review, commentary, editorial, etc. (scientific journal)  

  • Dynamic MRIによる胆嚢癌の早期診断

    吉満研吾, 柿原大輔, 入江裕之, 田嶋強, 浅山良樹, 平川雅和, 石神康生, 本田浩

    胆と膵   2005.5

    　More details

    Language：Japanese   Publishing type：Article, review, commentary, editorial, etc. (scientific journal)  

  • 腹部領域におけるマルチスライスCTの臨床的意義

    田嶋 強、吉満 研吾、柿原 大輔、上田 正信、入江 裕之、西江 昭弘、浅山 良樹、平川雅和、中山 智博、宇都宮 尚、本田 浩

    カレントテラピー   2005.5

    　More details

    Language：Japanese   Publishing type：Article, review, commentary, editorial, etc. (scientific journal)  

  • 膵癌のMDCT診断 －dynamic studyとMPR画像-

    入江裕之, 吉満研吾, 田嶋強, 浅山良樹, 平川雅和, 石神康生, 柿原大輔, 高山幸久, 本田浩

    胆と膵   2005.5

    　More details

    Language：Japanese   Publishing type：Article, review, commentary, editorial, etc. (scientific journal)  

  • 膵癌のMDCTによる術前進展度診断　－脈管・膵被膜浸潤などを中心に-

    入江裕之, 吉満研吾, 田嶋強, 浅山良樹, 平川雅和, 石神康生, 中山智博, 柿原大輔, 本田浩

    消化器外科   2005.5

    　More details

    Language：Japanese   Publishing type：Article, review, commentary, editorial, etc. (scientific journal)  

  • これだけでわかる画像による悪性腫瘍の病期診断 膵 臨床画像　200４　11月増刊号

    平川雅和, 田嶋強, 吉満研吾, 入江裕之, 浅山良樹, 石神康生, 柿原大輔, 本田浩

    臨床画像　200４　11月増刊号   2004.11

    　More details

    Language：Japanese   Publishing type：Article, review, commentary, editorial, etc. (scientific journal)  

  • 腎･尿路の画像診断　-MRIを中心に-

    西江昭弘, 吉満研吾, 入江裕之, 田嶋強, 浅山良樹, 平川雅和, 中山智博, 柿原大輔, 本田浩

    日本医事新報   2004.5

    　More details

    Language：Japanese   Publishing type：Article, review, commentary, editorial, etc. (scientific journal)  

  • MR imaging of renal cell carcinoma: its role in determining cell type.

    Yoshimitsu K, Irie H, Tajima T, Nishie A, Asayama Y, Hirakawa M, Nakayama T, Kakihara D, Honda H.

    Radiat Med. 2004   2004.5

    　More details

    Language：English   Publishing type：Article, review, commentary, editorial, etc. (scientific journal)  

  • 膵嚢胞性疾患とその鑑別診断

    入江裕之, 吉満研吾, 田嶋強, 西江昭弘, 浅山良樹, 平川雅和, 柿原大輔, 中山智博, 本田浩

    臨床放射線   2004.5

    　More details

    Language：Japanese   Publishing type：Article, review, commentary, editorial, etc. (scientific journal)  

  • 包括医療時代の肝イメージング

    入江裕之, 吉満研吾, 田嶋強, 西江昭弘, 浅山良樹, 平川雅和, 柿原大輔, 中山智博, 本田浩

    臨床画像   2004.5

    　More details

    Language：Japanese   Publishing type：Article, review, commentary, editorial, etc. (scientific journal)  

  • Preoperative intraarterial infusion chemotherapy for advanced gastric cancer--a retrospective review of four cases.

    Iida T, Hirata N, Hirakawa M, Noguchi T.

    Radiat Med.   2003.5

    　More details

    Language：English   Publishing type：Article, review, commentary, editorial, etc. (scientific journal)  

▼display all

Professional Memberships

  • Japan Radiological Society(JRS)

  • Japanese Society of Interventional Radiology

  • Japanease Society of Implantable Port Assisted Treatment

  • Japanese Society of Magnetic Resonance in Medicine

Committee Memberships

  • 日本医学放射線学会   代議員　放射線安全管理委員　保健委員　プログラム委員　画像診断ガイドライン委員   Domestic

    2021.4 - 2026.3   

  • 日本IVR学会   代議員   Domestic

    2019.6 - 2022.5   

  • 日本医学放射線学会総会   代議員   Domestic

    2019.4 - 2021.3   

  • 日本IVR学会   健保委員会   Domestic

    2017.6 - 2019.6   

  • 日本医学放射線学会   放射線安全管理委員会   Domestic

    2016.8 - 2018.4   

  • 日本放射線科専門医・医会   Executive   Domestic

    2015.7 - 2021.7   

  • 日本医学放射線学会   放射線防護委員   Domestic

    2014.6 - 2016.6   

  • 日本IVR学会   代議員   Domestic

    2014.6 - 2016.5   

  • 日本医学放射線学会   代議員   Domestic

    2014.4 - 2014.3   

  • 日本医学放射線学会   画像診断ガイドライン委員会委員   Domestic

    2012.1 - 2015.12   

  • 日本IVR学会   代議員   Domestic

    2011.6 - 2013.5   

▼display all

Academic Activities

  • プログラム委員 International contribution

    The 83rd Annual Meeting of the Japan Radiological Society  （ Yokohama Japan ） 2024.4

    　More details

    Type：Competition, symposium, etc. 

    Number of participants：10,000

  • プログラム委員 International contribution

    The 82nd Annual Meeting of the Japan Radiological Society  （ Yokohama Japan ） 2023.4

    　More details

    Type：Competition, symposium, etc. 

    Number of participants：10,000

  • Screening of academic papers

    Role(s)： Peer review

    2023

    　More details

    Type：Peer review 

    Number of peer-reviewed articles in foreign language journals：1

    Number of peer-reviewed articles in Japanese journals：2

  • プログラム委員 International contribution

    The 81th Annual Meeting of the Japan Radiological Society  （ Japan ） 2022.4

    　More details

    Type：Competition, symposium, etc. 

    Number of participants：10,000

  • 当番世話人

    第35回ミッドウィンターセミナー  （ Japan ） 2022.1

    　More details

    Type：Competition, symposium, etc. 

    Number of participants：900

  • Screening of academic papers

    Role(s)： Peer review

    2022

    　More details

    Type：Peer review 

    Number of peer-reviewed articles in foreign language journals：3

  • プログラム委員

    The 80th Annual Meeting of the Japan Radiological Society  （ Japan ） 2021.4

    　More details

    Type：Competition, symposium, etc. 

    Number of participants：10,000

  • Screening of academic papers

    Role(s)： Peer review

    2021

    　More details

    Type：Peer review 

    Number of peer-reviewed articles in foreign language journals：3

  • プログラム委員 International contribution

    The 79th Annual Meeting of the Japan Radiological Society  （ Japan ） 2020.5 - 2020.6

    　More details

    Type：Competition, symposium, etc. 

  • 座長

    第13回大分ラジオロジーミーティング  （ Japan ） 2020.1

    　More details

    Type：Competition, symposium, etc. 

  • Screening of academic papers

    Role(s)： Peer review

    2020

    　More details

    Type：Peer review 

    Number of peer-reviewed articles in foreign language journals：3

  • 当番世話人

    第24回肝動脈塞栓療法  （ Japan ） 2019.6

    　More details

    Type：Competition, symposium, etc. 

  • 一般演題　肝臓　座長

    第48回日本IVR学会総会  （ Japan ） 2019.5 - 2019.6

    　More details

    Type：Competition, symposium, etc. 

  • プログラム委員

    The 78th Annual Meeting of the Japan Radiological Society  （ Japan ） 2019.4

    　More details

    Type：Competition, symposium, etc. 

    Number of participants：10,000

  • 座長

    第32回JCRミッドウィンターセミナー  （ Japan ） 2019.1

    　More details

    Type：Competition, symposium, etc. 

    Number of participants：800

  • Screening of academic papers

    Role(s)： Peer review

    2019

    　More details

    Type：Peer review 

    Number of peer-reviewed articles in foreign language journals：2

    Number of peer-reviewed articles in Japanese journals：1

  • 座長

    JCRミッドサマーセミナー2018  （ Japan ） 2018.7

    　More details

    Type：Competition, symposium, etc. 

    Number of participants：800

  • Screening of academic papers

    Role(s)： Peer review

    2018

    　More details

    Type：Peer review 

    Number of peer-reviewed articles in foreign language journals：2

  • 座長（Chairmanship）

    第30回JCRミッドウィンターセミナー  （ Japan ） 2017.1

    　More details

    Type：Competition, symposium, etc. 

  • Screening of academic papers

    Role(s)： Peer review

    2017

    　More details

    Type：Peer review 

    Number of peer-reviewed articles in foreign language journals：3

  • 座長（Chairmanship）

    第45回日本IVR学会  （ Japan ） 2016.5

    　More details

    Type：Competition, symposium, etc. 

  • 座長（Chairmanship）

    第29回日本放射線科専門医会・医会　ミッドウィンターセミナー  （ Japan ） 2016.1

    　More details

    Type：Competition, symposium, etc. 

  • 座長（Chairmanship）

    第20回　呼吸器フォーラム  （ Japan ） 2014.3

    　More details

    Type：Competition, symposium, etc. 

  • 座長（Chairmanship）

    平成25年度　別府市医師会学術講演会  （ Japan ） 2014.2

    　More details

    Type：Competition, symposium, etc. 

  • 座長（Chairmanship）

    第6回大分ラジオロジーミーティング  （ Japan ） 2014.1

    　More details

    Type：Competition, symposium, etc. 

  • 座長（Chairmanship）

    第18回大分最少侵襲治療法研究会  （ Japan ） 2013.11

    　More details

    Type：Competition, symposium, etc. 

  • 座長（Chairmanship）

    大分ラジオロジー・ミーティング  （ Japan ） 2013.6

    　More details

    Type：Competition, symposium, etc. 

  • 座長（Chairmanship）

    大分ラジオロジー・ミーティング  （ Japan ） 2012.10

    　More details

    Type：Competition, symposium, etc. 

  • 座長（Chairmanship）

    大分ラジオロジー・ミーティング  （ Japan ） 2012.2

    　More details

    Type：Competition, symposium, etc. 

  • 座長（Chairmanship）

    大分ラジオロジー・ミーティング  （ Japan ） 2011.6 - 2013.6

    　More details

    Type：Competition, symposium, etc. 

  • 座長（Chairmanship）

    第231回　別府胃腸会特別講演会  （ Japan ） 2011.2

    　More details

    Type：Competition, symposium, etc. 

  • 座長（Chairmanship）

    日本IVR学会　九州地方会  （ Japan ） 2010.12

    　More details

    Type：Competition, symposium, etc. 

  • 座長（Chairmanship）

    日本IVR学会　九州地方会  （ Japan ） 2007.12

    　More details

    Type：Competition, symposium, etc. 

  • 座長（Chairmanship）

    日本医学放射線学会　九州地方会  （ Japan ） 2006.6

    　More details

    Type：Competition, symposium, etc. 

▼display all

Research Projects

  • 転写産物のロングリード・シーケンスによる食道癌化学放射線療法抵抗性獲得機構の解明

    Grant number：23K07066  2023.4 - 2026.3

    Grants-in-Aid for Scientific Research  Grant-in-Aid for Scientific Research (C)

    平木 嘉樹, 本村 有史, 平川 雅和, 三森 功士, 井上 大地

    　 More details

    Grant type：Scientific research funding

    進行食道扁平上皮癌に対する化学放射線療法(CRT)は標準治療の一つとされており高い抗腫瘍効果の期待できる低侵襲な治療法であるが、適応を決めるための感受性(抵抗性)の正確な予測は困難である。CRTによる治療成績向上のためには、感受性（抵抗性）に関与する(変異)転写産物を同定しその予測法の確立あるいは感受性を増感するための治療標的としての意義の確立が望まれる。近年、革新的技術であるロングリード・シーケンスの開発によりRNA全長のシーケンスが可能になった。すなわち発がんのドライバーとしてあるいはがん進展に関連する(変異)転写産物が注目されている。

    CiNii Research

  • 眼の水晶体等価線量限度に関する医療法改正対応への新たな線量計一体型防護眼鏡の開発

    Grant number：21K07702  2021 - 2023

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research  Grant-in-Aid for Scientific Research (C)

    平川 雅和, 本村 有史, 坂本 勝美, 高尾 誠一朗, 平木 嘉樹

    　 More details

    Authorship：Principal investigator  Grant type：Scientific research funding

    放射線を使用した画像下治療は手技複雑化等により術者被ばく増加による白内障が懸念される。一方、眼の水晶体等価線量限度に関する医療法施行規則一部改正が2021年4月より施行予定で水晶体等価線量限度低減「5年間の平均で20mSv/年かつ50mSv/年を超えない」と水晶体等価線量評価法の推奨変更「眼の近傍や全面マスクの内側に放射線測定器を装着」とされている。2023年3月までの経過措置はあるものの正確な水晶体等価線量評価と更なる水晶体被ばく防護が必要と考えられる。本研究は、レベルの高い放射線診療を提供しながらも放射線障害防止と法令遵守とを両立した新たな放射線診療体制の整備に貢献可能と考えられる。

    CiNii Research

  • Radiation dosimetry of Interventional radiological operator using direct eye dosimeter corresponding to new radiation dose limit of ICRP

    Grant number：18K07755  2018 - 2021

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research  Grant-in-Aid for Scientific Research (C)

    Hirakawa Masakazu

    　 More details

    Authorship：Principal investigator  Grant type：Scientific research funding

    In this research, there was no IR (interventional radiology) operators who evaluated the lens dose with neck glass dosimeter outside protective lead glasses and exceed the new occupational lens dose limit (20 mSv/year, averaged over defined periods of 5 years). In high volume center of IR, however, there may be some IR operators who may exceed the new occupational lens dose limit. The lens dose inside lead glasses which was estimated with the shieling effect and the lens dose of neck dosimeter tended to be lower and underestimated, compared to the eye lens dose by using a novel direct eye dosimeter, the DOSIRIS(Hp(3)) under protective glasses. This underestimated eye lens dose may cause the risk of radiation induced cataracts. Finally, To comply with new limit of eye dose and minimize the radiation-induced risk at the eye lenses, protective lead devices and correct evaluation of the eye dose using direct eye dosimeter like DOSIRIS under protective lead glasses might be needed.

    CiNii Research

  • 食道癌放射線治療新規標的としてmicroRNAのInVivoと臨床症例の統合解析

    Grant number：26461893  2014 - 2016

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research  Grant-in-Aid for Scientific Research (C)

    　 More details

    Authorship：Principal investigator  Grant type：Scientific research funding

  • 食道癌放射線治療成績向上のための放射線感受性制御ｍｉｃｒｏ　ＲＮＡと遺伝子の解明

    Grant number：23591843  2011 - 2013

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research  Grant-in-Aid for Scientific Research (C)

    　 More details

    Authorship：Principal investigator  Grant type：Scientific research funding

  • 血管内皮細胞を標的とした放射線増感剤としてのL-アルギニンの至適投与法の研究

    Grant number：19790880  2007 - 2009

    Grants-in-Aid for Scientific Research  Grant-in-Aid for Young Scientists (B)

    　 More details

    Authorship：Principal investigator  Grant type：Scientific research funding

  • 血管内皮細胞への放射線照射で誘導されるINOSの悪性腫瘍治療における意義

    Grant number：17790866  2005 - 2007

    Grants-in-Aid for Scientific Research  Grant-in-Aid for Young Scientists (B)

    　 More details

    Authorship：Principal investigator  Grant type：Scientific research funding

▼display all

Educational Activities

  • Training of radiology for clinical residents and fellows

Other educational activity and Special note

  • 2023  Special Affairs  九州大学病院別府病院　放射線取扱主任者として院内の放射線診療従事者に対する教育訓練を行っている

    　詳細を見る

    九州大学病院別府病院　放射線取扱主任者として院内の放射線診療従事者に対する教育訓練を行っている

  • 2023  Special Affairs  九州大学病院別府病院　放射線取扱主任者として院内の放射線診療従事者に対する教育訓練を行っている

    　詳細を見る

    九州大学病院別府病院　放射線取扱主任者として院内の放射線診療従事者に対する教育訓練を行っている

  • 2022  Special Affairs  州大学病院別府病院　放射線取扱主任者として院内の放射線診療従事者に対する教育訓練を行っている

    　詳細を見る

    州大学病院別府病院　放射線取扱主任者として院内の放射線診療従事者に対する教育訓練を行っている

  • 2021  Special Affairs  州大学病院別府病院　放射線取扱主任者として院内の放射線診療従事者に対する教育訓練を行っている

    　詳細を見る

    州大学病院別府病院　放射線取扱主任者として院内の放射線診療従事者に対する教育訓練を行っている

  • 2020  Special Affairs  九州大学病院別府病院　放射線取扱主任者として院内の放射線診療従事者に対する教育訓練を行っている

    　詳細を見る

    九州大学病院別府病院　放射線取扱主任者として院内の放射線診療従事者に対する教育訓練を行っている

  • 2013  Special Affairs  九州大学病院別府病院　放射線取扱主任者として院内の放射線診療従事者に対する教育訓練を行っている

    　詳細を見る

    九州大学病院別府病院　放射線取扱主任者として院内の放射線診療従事者に対する教育訓練を行っている

▼display all

Outline of Social Contribution and International Cooperation activities

  • 腹部・骨盤領域の画像診断・IVRに関して、放射線科医や放射線診療技師を対象に教育を行っている。
    癌に対するIVRや放射線治療法の確立のため、各種の臨床治験へ参加している。

Social Activities

  • J-RIME DRL-WG IVRプロジェクトチームリーダー

    2023

    　More details

    J-RIME DRL-WG IVRプロジェクトチームリーダー

  • 九州大学病院別府病院市民公開講座「こわがらないで放射線！　がん治療に有効です！」

    九州大学病院別府病院  別府  2019.6

    　More details

    Audience：General,　Scientific,　Company,　Civic organization,　Governmental agency

    Type：Lecture

  • 九州大学病院別府病院市民公開講座「こわがらないで放射線！　がん治療に有効です！」

    九州大学病院別府病院  大分県　宇佐ホテルリバーサイド  2018.10

    　More details

    Audience：General,　Scientific,　Company,　Civic organization,　Governmental agency

    Type：Lecture

  • 別府市医師会医療情報ネットワーク委員として、医療情報ネットワークである、「ゆけむり医療ネット」の運営等に携わっている。

    2018

    　More details

    別府市医師会医療情報ネットワーク委員として、医療情報ネットワークである、「ゆけむり医療ネット」の運営等に携わっている。

  • 第4回　九州大学病院別府病院　市民公開講座 演者

    九州大学病院別府病院  別府市　ビーコンプラザ  2016.8

    　More details

    Audience：General,　Scientific,　Company,　Civic organization,　Governmental agency

    Type：Lecture

    新たな３Dマンモグラフィ撮影法「トモシンセシス」が切り開く乳がん早期発見への挑戦

  • 肝動脈化学塞栓術　特別講演会

    エーザイ  北九州市  2015.3

    　More details

    Audience：General,　Scientific,　Company,　Civic organization,　Governmental agency

    Type：Lecture

    薬剤溶出性球状塞栓物質使用TACE:DEB-TACE -ディーシービーズ使用経験に基づくDEB-TACEとB-TACEとの治療法選択と融合-

  • 動注化学療法フォーラム2015・DEB-TACEコントロール不良症例からひも解くミリプラチン使用B-TACEの可能性

    大日本住友製薬  福岡  2015.2

    　More details

    Audience：General,　Scientific,　Company,　Civic organization,　Governmental agency

    Type：Lecture

    DEB-TACEコントロール不良症例からひも解くミリプラチン使用B-TACEの可能性

  • ミリプラエリアフォーラム　In　Kansai

    大日本住友製薬  大阪  2015.2

    　More details

    Audience：General,　Scientific,　Company,　Civic organization,　Governmental agency

    Type：Lecture

    肝細胞癌に対する局所制御能向上を目的として、2012年よりマイクロバルーンカテーテルを使用してMicroballoon-occluded transarterial chemoembolization (B-TACE) を施行している。主な使用抗癌剤は、ミチプラチンであるが、リピオドールとのsuspensionは、その粘調性の高さから、通常のTACEでは、薬剤、塞栓物質の注入が不十分な症例や治療後のリピオドール早期washout症例をしばしば経験する。肝動脈のマイクロバルーン閉塞により、治療域の血行動態の変化や薬剤、塞栓物質の逸脱を制御することにより、ミリプラチン使用B-TACEで、より良好な局所制御が得られる症例が増加した。今回、我々の施設での、肝細胞癌に対するミリプラチン使用B-TACEの手技や局所制御能について症例を中心に報告させていただく。

  • 第109回　大分整形外科症例検討会　特別講演会 整形外科領域の放射線治療　－重粒子線治療を中心としてー

    大分整形外科症例検討会  大分　ホルトホール  2015.1

    　More details

    Audience：General,　Scientific,　Company,　Civic organization,　Governmental agency

    Type：Lecture

  • 地域医療連携パス委員会委員

    別府市医師会  別府市医師会  2014.9

    　More details

    Audience：General,　Scientific,　Company,　Civic organization,　Governmental agency

    Type：Other

  • 九州大学病院別府病院　第1回市民公開講座 各診療科紹介 放射線科：九大別府病院の放射線診療の特徴　－CTコロノグラフィーと放射線治療ー

    九州大学病院別府病院  別府市亀の井ホテル  2013.8

    　More details

    Audience：General,　Scientific,　Company,　Civic organization,　Governmental agency

    Type：Lecture

    九大別府病院の放射線科で行っているCTコロノグラフィーと高精度放射線治療について概説する。CTコロノグラフィーと高精度放射線治療は大分県内でも、可能な医療施設は限られており、大腸がんの早期発見やあきらめないがん治療に貢献したい。

  • 平成24年度大分県医師会　がん精密検診協力医療機関研修会／大腸がん部門「大腸癌検診におけるCTコロノグラフィー」

    大分県医師会  大分市　大分県医師会  2013.1

    　More details

    Audience：General,　Scientific,　Company,　Civic organization,　Governmental agency

    Type：Seminar, workshop

    大腸癌の検診において、迅速、簡単、安全といわれているCTコロノグラフィーの概要・検診における位置づけ、役割について概説し、CTコロノグラフィーの普及により大腸癌検診の受診率向上を目指すものである。

  • 第273回　北九州画像診断部会　特別講演　「感謝されるIVRを目指して」

    共催　北九州画像診断部会・バイエル薬品  北九州市　小倉  2012.1

    　More details

    Audience：General,　Scientific,　Company,　Civic organization,　Governmental agency

    Type：Lecture

    IVRは、画像介入下低侵襲治療であり、近年、その有効性が話題となっており、臨床現場での必要性は大きなものである。本講演では、患者様に喜ばれ、良好な治療成績を収めるIVRに関して、術前因子や手技に関するポイント等を発表する。

  • 別府市医師会　マンモグラフィー読影委員会委員

    別府市医師会  2010.12

    　More details

    Audience：General,　Scientific,　Company,　Civic organization,　Governmental agency

    Type：Research consultation

  • 別府市　地域保健センター機器選定委員会委員

    別府市医師会  2009.12

    　More details

    Audience：General,　Scientific,　Company,　Civic organization,　Governmental agency

    Type：Other

  • 進化し続ける画像診断と放射線治療

    別府医師会  別府医師会  2009.4

    　More details

    Audience：General,　Scientific,　Company,　Civic organization,　Governmental agency

    Type：Lecture

  • 最新画像診断装置による｢がんと血管病」の早期発見と身体にやさしい放射線治療

    九州大学病院　別府先進医療センター  トキハデパート  2009.2

    　More details

    Audience：General,　Scientific,　Company,　Civic organization,　Governmental agency

    Type：Lecture

  • 最新画像診断と高精度放射線治療の可能性

    別府市医師会  別府市医師会  2009.2

    　More details

    Audience：General,　Scientific,　Company,　Civic organization,　Governmental agency

    Type：Lecture

  • 第8回　別府先進医療センター　市民公開講座 最新画像診断装置による｢がんと血管病」の早期発見と身体にやさしい放射線治療

    九州大学病院　別府先進医療センター  2008.6

    　More details

    Audience：General,　Scientific,　Company,　Civic organization,　Governmental agency

    Type：Lecture

▼display all

Media Coverage

  • 肝臓がんの最新の血管内治療について、九州大学病院別府病院にて、施行されているマイクロバルーン閉塞下肝動脈化学塞栓療法ならびに薬剤溶出性球状塞栓物質使用肝動脈化学塞栓療法の治療法を元に、治療のメカニズムや対象患者様、治療成績、当院での取り組みについて紹介した。 Newspaper, magazine

    大分合同新聞  2015.7

    　More details

    肝臓がんの最新の血管内治療について、九州大学病院別府病院にて、施行されているマイクロバルーン閉塞下肝動脈化学塞栓療法ならびに薬剤溶出性球状塞栓物質使用肝動脈化学塞栓療法の治療法を元に、治療のメカニズムや対象患者様、治療成績、当院での取り組みについて紹介した。

  • 肝細胞がんに対する新たなマイクロバルーンカテーテルによる動脈化学塞栓療法に対して日本医学放射線学会で学会賞受賞に対する取材と本治療法の紹介をした。 Newspaper, magazine

    今日新聞  2014.5

    　More details

    肝細胞がんに対する新たなマイクロバルーンカテーテルによる動脈化学塞栓療法に対して日本医学放射線学会で学会賞受賞に対する取材と本治療法の紹介をした。

  • がん診療における放射線治療 Newspaper, magazine

    大分合同新聞  2014.4

    　More details

    がん診療における放射線治療

  • 九大病院別府病院の研究から　「重粒子線治療」 Newspaper, magazine

    大分合同新聞  2013.6

    　More details

    九大病院別府病院の研究から　「重粒子線治療」

  • 九大病院別府病院の臨床と研究から 放射線治療が得意ながん・不得意ながん Newspaper, magazine

    大分合同新聞  2012.6

    　More details

    九大病院別府病院の臨床と研究から
    放射線治療が得意ながん・不得意ながん

  • おおいた医療最前線　現場リポート CTコロノグラフィー Newspaper, magazine

    大分合同新聞  2012.1

    　More details

    おおいた医療最前線　現場リポート
    CTコロノグラフィー

  • 病院の実力　「泌尿器科がん」 前立腺がんに対する放射線治療 Newspaper, magazine

    読売新聞  2012.1

    　More details

    病院の実力　「泌尿器科がん」
    前立腺がんに対する放射線治療

  • 体を読み解く　九州大学別府病院の研究から 「がんに対する放射線治療最前線」 Newspaper, magazine

    大分合同新聞  2011.6

    　More details

    体を読み解く　九州大学別府病院の研究から
    「がんに対する放射線治療最前線」

▼display all

Travel Abroad

  • 2017.2

    Staying countory name 1：Thailand   Staying institution name 1：Bangkok General Hospital Department of Radiology

    Staying countory name 2：Thailand   Staying institution name 2：Siriraj Hospital Department of Radiology

    Staying countory name 3：Singapore   Staying institution name 3：Sigapore General Hospital Department of Radiology

    Staying countory name (Other)：Shingapole   Staying institution name (Other)：TAN TOCK SENG HOSPITAL Department of Radiology

  • 2004.8 - 2008.9

    Staying countory name 1：United States   Staying institution name 1：University of Rochester　Strong Memorial Hospital Interventional Radiology

Specialized clinical area

  • Biology / Medicine, Dentistry and Pharmacy / Internal Medicine / Radiology

    腹部画像診断　IVR（画像下治療）　放射線防護

Clinician qualification

  • Specialist

    Japan Radiological Society（JRS）

  • Specialist

    日本血管造影・インターベンショナルラジオロジー学会

  • Certifying physician

    日本乳がん検診精度管理中央機構

Year of medical license acquisition

  • 1995

Notable Clinical Activities

  • 悪性腫瘍に対する経血管的治療および経皮的治療、IVR 2013年より肝臓がんに対するマイクロバルーン閉塞下肝動脈塞栓化学療法（B-TACE)を施行し、従来に治療法より治療効果、有害事象で良好な治療成績を得ており、学会等でも一定の評価を得ている。 2014年より薬剤溶出性球状塞栓物質使用した肝動脈化学塞栓療法（DEB-TACE）も、肝臓がんに対して、施行している。上記B-TACEとDEB-TACEを組み合わせることで、肝臓がん患者様の病勢制御、生存期間延長を得つつある。 2015年には、日本IVR学会および ISIR & APCIO の国際Joint meetingにおいて、セミナーの講師を務め、上記肝動脈化学塞栓療法の治療法解説や有効性について講演した。 近年は、上記の加えて、IVRにおける被ばく低減に関する研究を進めている